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Abstract 
Prevalence rates of youth prescribed psychotropic medications have risen dramatically 
over the past decade.  Many of these medications are prescribed to treat symptoms of a 
disorder that occur in the school setting.  Some medications have negative side effects 
that can inhibit academic and social performance.  School psychologists have been 
identified as professionals who are equipped to assist in monitoring both the beneficial 
and negative effects of medications for youth attending school.  This study investigated 
the practices, training, types of disorders for which medication monitoring occurs, 
facilitators, and barriers to school psychologists engaging in medication monitoring in the 
schools.  Survey data from 166 members of the Florida Association of School 
Psychologists were collected and analyzed.  Seventy four percent of respondents 
endorsed medication monitoring as an appropriate role for school psychologists.  
Approximately half of the respondents in this study reported engaging in medication 
monitoring over the past school year.  Over half the sample reported receiving training 
related to medication monitoring.  Weak relationships were found among demographic 
and training variables and reported medication monitoring practices.  Additionally, none 
of the interactions between demographic, professional background, and training variables 
was predictive of medication monitoring practices.  Implications of these findings are 
discussed in relation to developing strategies to promote the medication monitoring 
practices of school psychologists. 
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           Chapter One 
           Introduction 
Statement of the Problem 
Utilization rates of psychotropic medications, particularly in youth, have 
increased dramatically over the past decade.  Zito (2003) reported a three-fold increase in 
the overall utilization rates of psychotropic medications in children and adolescents aged 
4-19 years from 1987-1996.  A 10-fold increase was observed for antidepressant 
medications for children and adolescents insured by Medicaid, and a five-fold increase 
was observed across children and adolescents insured by health maintenance 
organizations (HMOs [Zito, 2003]).  Utilization rates of psychotropic medications 
prescribed to treat disorders such as Autism Spectrum Disorder, Asperger’s syndrome, 
Obsessive Compulsive Disorder, and Conduct Disorder also have increased dramatically 
over the past decade (Abrams, Flood, & Phelps, 2006).  Research targeting children 
receiving special education services found that 39% of these children are prescribed a 
psychotropic medication including stimulants, antipsychotics, antidepressants, and 
antihypertensive medications to inhibit externalizing behaviors (Mattison, 1999).  
Additionally, Mattison reported 17% of students receiving special education services 
were administered multiple medications.   
Given these high utilization rates of psychotropic medications among school-aged 
youth, monitoring the effects of these medications is needed.  Psychotropic medications 
are typically prescribed to treat both externalizing and internalizing symptoms of 
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emotional and behavioral disorders such as Attention-Deficit/Hyperactivity Disorder 
(ADHD), Oppositional Defiant Disorder, anxiety disorders, depressive disorders, and 
autism spectrum disorders (American Psychological Association [APA] Working Group 
on Psychoactive Medications for Children & Adolescents, 2006).    
Many psychotropic medications have potentially serious side effects in youth.  
Specifically, the Food and Drug Administration (FDA) issued “black box” warnings on 
certain classes of medications prescribed to children and adolescents under 18 years of 
age, warning of serious potential side effects.  The black box warning is the strongest 
warning available from the FDA.  Side effects of some psychotropic medications may 
include suicidal ideation, acute seizures, cognitive/psychomotor impairment, and sudden 
increases or decreases in blood pressure resulting in acute episodes of hypotension or 
hypertension which can cause sudden fainting or headaches and blurred vision (APA 
Working Group, 2006; FDA, 2005).  
Of additional concern is the fact that many psychotropic medications prescribed 
to youth are only approved by the FDA for use with adults; in other words, they are being 
used off-label or without documented efficacy in pediatric populations (Bush, 2006).  The 
common practice in pediatrics of extrapolating adult doses of medications approved by 
the FDA to children is fraught with problems (Bush, 2006).  For instance, drug 
absorption, metabolism, and secretion in children and adolescent’s bodies can be 
markedly different than adults (Christensen, Helms, & Chesney, 1999).  As a result, close 
monitoring of the effects (both beneficial and detrimental) of psychotropic medications is 
needed to ensure children and adolescents’ response to medication does not impede 
academic and/or social-emotional functioning (Christensen et al., 1999).     
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Effects and Risks of Psychotropic Medications on Behavioral and Social 
Functioning 
 The APA Working Group (2006) offers the most up-to-date, comprehensive 
review of psychotropic medications and effects on childhood disorders. The disorders 
reviewed include: (a) Attention-Deficit/Hyperactivity Disorder (ADHD); (b) 
Oppositional Defiant Disorder (ODD); (c) Conduct Disorder; (CD); (d) Tourette and tic 
disorders; (e) Obsessive–Compulsive Disorder (OCD); (f) anxiety disorders; (h) 
depressive disorders; (i) bipolar disorder; (j) schizophrenia; and (k) autism spectrum 
disorder.  The effects of some medications can be profound (e.g., permanent involuntary 
motor tics which resemble Parkinsonian symptoms known as extrapyramidal symptoms) 
while polypharmacy, the practice of combining different classes of medications to 
diminish side effects of other medications, can have potentially dangerous health risks as 
well as unpredictable effects on social and academic functioning  (Christensen et al., 
1999).  
Combining multiple psychotropic medications to counteract side effects is 
commonplace (Christensen et al., 1999).  For example, it is common for children taking 
stimulant medications to also be prescribed a medication off-label (e.g., Clonidine or 
Tenex) to counteract insomnia.  However, many medications prescribed to counteract 
effects of stimulant medications can have significant and sudden side effects for which 
careful monitoring is required. For example, Clonidine, an anti-hypertensive medication 
commonly prescribed off-label to treat insomnia in children taking stimulants, can 
produce sudden drops in blood pressure otherwise known as hypotension (Christensen et 
al., 1999).   Alternatively, if this medication is suddenly stopped (e.g., parent or school 
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personnel forget to administer the medication) a dangerous sudden rise in blood pressure 
(hypertension) may occur (Kratochvil, Lake, Pliszka, & Walkup, 2005).  Many classes of 
medication have side effects (e.g., headaches, nausea, anxious symptoms, loss of 
academic skills due to medication side effects, and lethargy) that can negatively impact 
school functioning (APA Working Group, 2006).  Further, different doses of medications 
can mitigate negative side effects significantly once a proper dosage is found.   Lastly, 
there is a paucity of data related to appropriate dosages as well as long-term safety of 
medication prescribed to youth (APA Working Group, 2006).  
Medication Monitoring in Schools 
Public school personnel are playing an ever increasing role in pharmacological 
treatment of school-aged children.  Non-medical school personnel (e.g., secretaries and 
instructional assistants) are required to dispense psychotropic medications including 
controlled medications with little or no supervision, particularly in rural areas of the 
country (DuPaul & Carlson, 2005).   As a result, the probability of medication errors such 
as the inability to determine if a child took the medication, overdosing, and giving the 
incorrect medication to a student increases (DuPaul et al., 2005).  Monitoring the 
effectiveness as well as negative side effects of medications is needed.   The school 
psychologist has been identified as a professional, positioned in the school setting, who 
possesses unique training that is well-suited for medication monitoring.  Specifically, 
school psychologists’ knowledge and skills in consultation, problem solving, behavioral 
observations, intervention planning, and progress monitoring position them as ideal 
professionals within the education system to assist in the collection of data for the 
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purposes of progress monitoring the effects of medication (Grier & Bradley-Klug, in 
press; Power, DuPaul, Shapiro, & Kazak, 2003; Stoner, Carey, Ikeda, & Shinn, 1994).   
A study conducted by Guerasko-Moore, DuPaul, and Power (2005) examined 
school psychologists’ medication monitoring practices for children and adolescents being 
treated for symptoms related to ADHD.  The researchers examined perceptions, training, 
practices, and perceived barriers to medication monitoring.  Results indicated 54.5% of 
school psychologists reported engaging in medication monitoring and the majority 
reported this was an important professional role.  Teacher and parent rating forms, 
interviews, direct observation, and review of work samples were perceived by school 
psychologists as the most effective, acceptable, and feasible monitoring methods. The 
majority of school psychologists (58.1%) reported not receiving formal training in 
medication monitoring.  Additionally, receiving formal training (e.g., university-based 
class) on medication monitoring significantly increased the likelihood a school 
psychologist reported engaging in medication monitoring. The greatest facilitator of 
medication monitoring was teacher support.  Barriers to medication monitoring were time 
and accessibility of physicians to collaborate.  Although this study provides information 
regarding the medication practices of school psychologists related to youth with ADHD, 
additional research is needed to determine whether these findings extend to the 
monitoring of other medications frequently prescribed to school-age children and 
adolescents. 
Facilitating and maintaining collaborative partnerships between school personnel 
and primary care providers (e.g., pediatricians) is another important aspect of medication 
monitoring (Grier & Bradley-Klug, in press).  Haile-Mariam, Bradley-Johnson, and 
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Johnson (2002) found the majority of physicians (81%) were interested in more 
information from schools related to behavioral observations, academic performance, and 
intellectual functioning. Additionally, the majority of physicians reported the type of 
information they often receive (e.g., lengthy psychoeducational reports) is not useful due 
to time constraints of the physician.  Wodrich and Landau (1999) recommend building a 
working relationship between primary care pediatrics and school psychologists, 
particularly for children with medical concerns. Developing concise methods of 
conveying information that respects both parties’ time constraints is an important 
consideration when forging working alliances.  School psychologists and pediatricians 
can develop working alliances for school-age children taking medications that may 
impact academic as well as social-emotional functioning.  
Rationale for the Study 
 Current research indicates the utilization rates of psychotropic medications 
prescribed to school-age children is on the rise (Abrams, Flood, & Phelps, 2006;  Zito, 
2003).  Many of the current psychotropic medications being used in pediatric populations 
have no randomized controlled trials demonstrating their efficacy in this population. As a 
result, many psychotropic medications are approved for use in adults but are prescribed 
off-label to children. In many cases, the side-effects and long-term impact on academic 
and social-emotional functioning in children have not been studied.  Some effects are 
directly linked to academic performance (e.g., memory loss, loss of academic skills or 
cognitive/psychomotor impairment) which may go unnoticed by other school personnel 
without training in assessment and progress monitoring.  Therefore, examining how 
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school personnel, specifically school psychologists, can assist in monitoring the effects of 
medications on youth during school hours is needed.    
Purpose of the Study  
This study sought to address gaps in the literature related to school psychologists’ 
medication monitoring practices for the most commonly prescribed medications 
including stimulants, antipsychotics, Alpha 2 agonists, typical and atypical neuroleptics, 
selective seratonin reuptake inhibitors (SSRIs), tricyclics, and benzodiazepines.  
Although  research has found over half of school psychologists surveyed reported 
engaging in medication monitoring as part of their practice (Gureasko-Moore, et al., 
2005), research to date has not examined the medication monitoring practices of school 
psychologists beyond medications used to treat symptoms of ADHD.  Current utilization 
rates suggest a significant number of youth in our schools are prescribed a variety of 
psychotropic medications to treat diverse symptoms of the most common disorders of 
youth (e.g., anxiety disorders, depressive disorders, ODD, autism spectrum disorders 
[Abrams, Flood, & Phelps, 2006; Mattison, 1999]).  
Research Questions 
1. Do school psychologists believe medication monitoring is a role in which they 
should be engaged? 
2. What is the relationship between school psychologists  
beliefs regarding medication monitoring as part of their role and their likelihood 
of engaging in medication monitoring in practice? 
3. What are the current medication monitoring practices of school psychologists? 
a) What types of data are collected when engaged in medication monitoring?  
 8 
 
b) What is the frequency (e.g., daily, weekly, or monthly) that medication 
monitoring data are collected? 
c) What is the frequency (e.g, daily, weekly, or monthly) that medication 
monitoring data are shared?  
d) With whom is medication monitoring information shared (e.g., 
   primary care provider, school nurse, teachers, parents)? 
4. What types of training (pre-service vs. in-service) do school psychologists receive 
in the practice of medication monitoring?  
5. What are the perceived barriers and facilitators to medication monitoring? 
6. What is the direction and strength of the relationship between geographic 
location, degree level, training program philosophy, type of school served, types 
of training reported related to medication monitoring and frequency of medication 
monitoring by school psychologists?  
Significance of the Study 
 This study built on existing literature that examined medication monitoring 
practices of school psychologists related to stimulant medications to treat symptoms of 
ADHD (Gureasko-Moore et al., 2005).  Identification of medication monitoring practices 
currently employed, types of training school psychologists have received related to 
medication monitoring, and what methods for monitoring medications (e.g., behavioral 
observation, behavior rating scales, review of academic work) school psychologists feel 
are the most effective and acceptable in their practice were examined.  This information 
will inform both pre-service and in-service practices related to medication monitoring.  
Additionally, identification of the facilitators and barriers to monitoring medications 
(e.g., time, training, and support from teachers) can be used to assist school psychologists 
 9 
 
in implementing systems-wide efforts to more effectively engage in medication 
monitoring.   
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 Chapter Two 
  Review of Related Literature 
Overview 
 This chapter provides a review of the literature relevant to this study.  The present 
study examined medication monitoring practices of school psychologists for students 
currently prescribed psychotropic medications.  Specifically, a survey was utilized to 
examine current practice, training (pre-service and in-service), perceived effectiveness of 
specific procedures, and perceived barriers related to medication monitoring.  A literature 
review was conducted to examine the current state of research on medication monitoring 
by school psychologists.  This review of relevant literature is divided into seven primary 
areas, including: 1) prevalence rates of children and adolescents prescribed psychotropic 
medications; 2) risks of psychotropic medication use in children and adolescents; 3) 
effects of psychotropic medications on academic and social functioning; 4) role of the 
public school personnel in medication administration; 5) legal and ethical issues, 6) 
medication monitoring practices in public schools; and 7) role of the school psychologist 
in medication monitoring.  
Prevalence of Children and Adolescents Prescribed Psychotropic Medications  
  Current research is equivocal regarding the utilization rates of psychotropic 
medications in youth populations. For the purposes of this literature review utilization 
rates are defined as the overall percentage of psychotropic medication prescribed for use 
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in a given population. Zuvekas, Vitiello, and Norquist (2006) examined trends in 
utilization rates of stimulant medications in children ages 0-18 years in the United States.  
Specifically, these researchers used the Medical Expenditure Panel Survey (MEPS), a 
nationally representative sample of U.S. households from the years 1997-2002.  The 
MEPS is a household survey of health care use and costs conducted by the National 
Center on Health Statistics.  The overall response rate for years 1997-2002 was 66.4%.  
Sample sizes for years 1997-2002 ranged from 7,235 to 11,713 randomly sampled 
households.  Data on prescription drug use were collected directly from households 
responding to the survey.  Results indicated the utilization rates of stimulant medication 
use among children and adolescents under 19 years of age was 2.7% in 1997 and 2.9% in 
2002.  The researchers indicate this is not a statistically significant change over the five 
year period.  Use of stimulants was highest among 6-12 year olds at 4.8% in 2002 and 
lowest among preschool aged children (under 6 years old) at 0.3% in 2002.  Additionally, 
the researchers found current use of stimulant medications was highest in males (4.0% in 
2002) compared to 1.7% for females.  Use of stimulant medications was also highest for 
Caucasian children (3.6%), while 2.2% for African American children and 1.4% for 
Hispanic children.  Respondents who did not have insurance had lower stimulant 
utilization rates (0.9%) than those with publicly funded health insurance (i.e., Medicaid) 
(3.3%) or private health insurance (3.0%).  Notably, the researchers also found variable 
utilization rates of stimulant medications based on region.  Specifically, the Southeast 
region of the U.S. had utilization rates of 3.4% overall compared to the Western region of 
the U.S. at 2.2%.  Significant increases in utilization rates in the Northeast region of the 
U.S., from 1.6% in 1997 to 2.7% in 2002 were reported.   
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 Overall, this survey examined utilization rates of stimulant medications in 
children under 19 years of age across the U.S.  The results indicated relatively stable 
utilization rates with some regional differences (i.e, greater prevalence in the Southeast).  
However, this study has limitations.  Specifically, the study relied on participants’ self-
report to accurately recall information.  It is possible that self-report bias could result in 
under or over-reporting of stimulant utilization.   
Other researchers have examined utilization rates for a variety of psychotropic 
medications.  Zito et al. (2003) conducted a study examining changes in the utilization 
rates of psychotropic medications for children and adolescents over a 10-year period.  
Specifically, these researchers used a population-based analysis of 900,000 children and 
adolescents enrolled in two U.S. healthcare systems.  Medicaid data from two states and 
dispensing records from a large private health maintenance organization (HMO) were 
utilized.  The results found at least six percent of children and adolescents being served 
by Medicaid and HMO insurance organizations had been prescribed a psychotropic 
medication across all geographic areas of the U.S.  Zito et al. (2003) reported a three-fold 
increase in utilization rates of psychotropic medications in children and adolescents over 
the 10-year period of the study.  Significant increases were found among specific drug 
classes as well.  The largest increase in utilization rates across both HMO and Medicaid 
populations was dextroamphetamine (Adderall).  This medication is typically used for the 
treatment of Attention-Deficity/Hyperactivity Disorder (ADHD), which accounted for a 
7-fold increase among Medicaid populations and a 14-fold increase among the HMO 
population.  The second largest increase in utilization rates was for antidepressant 
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medications.  A 10-fold increase was observed across Medicaid populations while a 5-
fold increase was observed across the HMO population.   
Zito and colleagues (2003) hypothesized the dramatic increase in antidepressant 
use among children and adolescents were due to the overall increase in use of selective 
serotonin reuptake inhibitors (SSRIs) among adult populations.  As prescriptions for 
SSRIs increased in adult populations, physicians began prescribing these medications at 
increasing rates to children and adolescents as well.  Some classes of psychotropic 
medications were used with significantly greater prevalence among Medicaid populations 
than the HMO population.  Neuroleptics, anticonvulsents used as mood stabilizers, and 
lithium were utilized at a much greater rate among the Medicaid populations. These 
medications are typically used to treat psychotic symptoms and to control violent 
externalizing behaviors (Weller, Rowan, Elia, & Weller, 1999).  Specifically, as a group, 
these psychotropic medications were utilized at a rate in the Medicaid populations twice 
as frequently as in the HMO population.  Age specific patterns across both the Medicaid 
populations and the HMO population were also investigated.  The greatest changes for 
Medicaid populations with respect to psychotropic medication utilization occurred in the 
10 to 14 year old group in 1997. Specifically, this group had the greatest overall 
utilization rate among all children and adolescents under 19 years of age.  The 
researchers hypothesized this may be in part due to the longer duration of this population 
receiving stimulant medications and then receiving other psychotropic medications to 
treat other symptoms (e.g., violent externalizing behaviors).  The 5-9 year old group was 
the previous Medicaid population with the highest utilization rate in 1987. With respect 
to the HMO group, in 1997, 15-19 year olds had the highest utilization rate of 
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psychotropic medications, replacing the 10-14 year old group which had the highest 
utilization rate in 1987 (Zito et al., 2003).  
 With respect to gender, Zito and colleagues (2003) found males were prescribed 
psychotropic medications at a rate twice that of females across the 10-year time period.  
Additionally, they found the male to female utilization rates were greater in the Medicaid 
populations than the HMO population.  Boys were being prescribed antidepressants at a 
significantly greater rate than the previous decade and utilization rates for stimulant 
medications continued to be greater for boys than girls, although the disparity decreased 
over the ten-year period. Dopamine agonists (mainly Clonidine) rose from near non-use 
in the previous decade to marked increases across the time span of the study. Increased 
utilization rates of neuroleptics and lithium were noted. 
 With respect to race, data were only available for individuals in the Medicaid 
populations.  Within this sample, there was no change in Caucasian and African 
American utilization ratios over the 10-year period.  Specifically, the disparity between 
the two groups remained stable, particularly with respect to the use of antidepressants 
being utilized by the Caucasian sample at a far greater extent. Overall disparities in 
prescription of psychotropic medications related to race and other characteristics were 
consistent with data from the National Ambulatory Medical Care Study (NAMCS) which 
will be described below in detail (Goodwin, Gould, Blanco, & Olfson, 2001).   
 Goodwin et al. (2001) examined data from a nationally representative study 
(NAMCS) of 166,256 office visits to physicians (i.e., pediatricians, psychiatrists, child 
and adolescent psychiatrists, and general practitioners) for children and adolescents 19 
years old and under.  The researchers examined utilization rates of psychotropic 
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medications.  The results indicated psychotropic medications were prescribed to children 
and adolescents 19 years of age and younger 2.2% of the total office visits.  For office 
visits in which a psychotropic medication was prescribed, stimulant medications were the 
most frequent (54%) while antidepressants were second most frequently prescribed 
followed by (30%); anxiolytics (7.2%); antipsychotics (including anticonvulsants; 7.2%); 
and mood stabilizers (12.7%).  The significant majority of psychotropic medications were 
prescribed by general practitioners (e.g., family physicians) and pediatricians (85.4%) 
compared with specialists (e.g., child and adolescent psychiatrists).  
 Consistent with Zito et al. (2003), male children and adolescents were more likely 
to be prescribed a psychotropic medication, particularly stimulants.  With respect to race, 
Caucasian children and adolescents were prescribed a psychotropic medication at a 
greater rate than children and adolescents of other races with the exception of stimulants.    
 Additionally, significant differences were noted among payment source (i.e., 
HMO vs. Medicaid).  Specifically, if a child or adolescent used Medicaid as their 
insurance, they were more likely to be prescribed certain classes of psychotropic 
medications such as antipsychotics, anxiolytics, and mood stabilizers.  Several 
hypotheses for this phenomenon were presented.   Specifically, children and adolescents 
who utilize Medicaid are likely to be from low socioeconomic status (SES) households.  
Research has linked low SES with an increased risk for mental illness (Buck, 1997).  
 Frazier and colleagues (2011) examined the prevalence and correlates of 
psychotropic medication use in adolescents with a diagnosis of autism spectrum disorder 
(ASD) who also were diagnosed with Attention Deficit/Hyperactivity Disorder (ADHD) 
as well as youth only diagnosed with ADHD or ASD.  Data from the National 
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Longitudinal Transition Study, a 10 year prospective study with data collected from 2000 
to 2009, were examined. The study included a nationally representative sample (n = 
11,000) of adolescents ages 13-17 who received special education services.  Youth who 
were diagnosed with both ASD and co-occurring ADHD had the highest (58%) rates of  
psychotropic medication use while youth with only ADHD had a 49% usage rate.  Youth 
with only an ASD diagnosis had the lowest usage rate in the study of 34%.   Strengths of 
this study include the large nationally representative sample and the fact that data are 
relatively current.  Weaknesses in this study include the reliance on parent self-report 
data and the restricted age range of participants.  As such, this study does not offer data 
relevant to children below the age of 13 years.  
 More recently, Pringle and colleagues (2012) examined data from the Survey of 
Pathways to Diagnosis and Services which is a nationally representative survey of 
school-aged children with special health care needs aged 6-17 who have been diagnosed 
with autism spectrum disorder, intellectual disability, or a developmental delay.  The 
researchers re-contacted, via telephone, parents of children who participated in the 
original Survey of Pathways to Diagnosis and Services study in 2009 which examined 
factors related to how families access care, received a diagnosis, and the frequency and 
types of treatments and interventions accessed for their children.   Eighty-seven percent 
of the participants in the original study agreed to participate in the follow-up phone 
interview.  Pringle et al. (2012) found over one-half of all school-aged children diagnosed 
with autism spectrum disorders (ASD) are prescribed at least one psychotropic 
medication and almost one-third of school aged children with ASD use stimulant 
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medications.  Additionally, one-quarter of children with ASD take anti-anxiety or mood 
stabilizing medications and one-fifth are prescribed antidepressant medications.   
 The strengths of this study included how recently it was conducted, the large 
nationally representative sample size from which the results were drawn and the 
relatively high (87%) rate of families who agreed to be re-interviewed about what 
medications their children are currently taking. Additionally, the study employed an age 
range (6 to 17 years) of child participants that closely matches the school age population.  
Other researchers have found large numbers of children receiving special 
education services for emotional and behavior disorders are being prescribed 
psychotropic medications.  Mattison (1999) conducted a study in which three year usage 
of psychotropic medications among elementary school students in the Midwestern U.S. 
who were receiving special education services under the category of serious emotional 
disturbance was investigated.  A total of 89 students ages 7-18 years participated in this 
study. Using parent report data, 39% of the total sample of 89 students were reported to 
be taking a psychotropic medication at the beginning of the three-year data collection.  
Specifically, 26% were being prescribed stimulant medication while the remaining 
students were being administered antipsychotics, antidepressants, and the 
antihypertensive medication Clonidine as an off-label medication. Additionally, the 
researchers found 17% of students were being administered multiple medications.  A 
portion of the students in this study were administered various medications at different 
points throughout the study. Specifically, 24% received a psychotropic medication 
consistently across the entire three-year span of the study.  This study is the only one of 
its kind at the time of writing to specifically examine the prevalence of psychotropic 
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medication usage in students receiving special education services under the diagnostic 
label of serious emotional disturbance.    
Overall, the studies presented relating to psychotropic utilization rates indicate 
school-age children are prescribed psychotropic medications at a rate that has risen 
dramatically over the past decade.  While Zuvekas et al. (2006) found stimulant 
medications remained relatively stable, other researchers examining a broader scope of 
psychotropic medication utilization rates in children found significant increases in other 
classes of psychotropics (e.g., antidepressants, neuroleptics, and lithium).  Further, 
children with co-morbid diagnoses were found to have the highest utilization rates 
(Frazier et al., 2011).  Children in emotional and behavior disorder special education 
classes utilize psychotropic medications at significantly greater rates than the overall U.S. 
population when comparing utilization rates across studies.   
The aforementioned studies are limited by the lapse in time between data 
collection and publication. Additionally, the study by Mattison (1999) used a small 
sample size which limits generalization of the results to the entire U.S. population.  This 
was not a limitation in the other studies reviewed as the researchers utilized larger and 
more representative samples.  Overall, the studies yield important information on the 
current utilization rates across the U.S. with respect to psychotropic medication use in 
children and adolescents.   
Risks of Psychotropic Medication Use in Children and Adolescents 
With the reported increase in use of psychotropic medications, there is a related 
concern as to the short-and long-term side effects of these medications on children and 
adolescents.  The amount of evidence on the short-and long-term effects of medications 
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to treat various childhood disorders has been lacking.  This had lead to the FDA issuing 
“black box” warnings on certain classes of medications used in children and adolescents 
under 18 years of age warning of serious potential side effects (e.g., suicidal ideation; 
Food and Drug Administration, 2005).   
 Bush (2006) articulates the real and potential risks of widespread off-label 
prescribing of psychotropic medications to children.  Off-label prescribing refers to the 
use of medications outside of the Food and Drug Administration guidelines for use.  
Specifically, a medication may be approved for use for a certain condition but is 
prescribed off-label to treat another condition based upon a clinician’s judgment.  For 
example, Clonidine is an anti-hypertensive agent originally approved to treat high blood 
pressure but is frequently prescribed to treat symptoms of ADHD in children.  Bush 
(2006) discusses the paucity of clinical trials involving children and the widespread off-
label prescribing of medications which have never been studied in children.  Bush gives 
several plausible hypotheses for the lack of clinical trials involving children.  
Specifically, as pharmaceutical companies are for-profit businesses, clinical trials which 
may not lead to significant future profits may be de-emphasized while other clinical trials 
may be given priority (e.g., adult clinical trials). Children are typically prescribed 
medications for shorter durations than adults leading to less of the medication being 
needed and therefore, less profit.   
Christensen, Helms, and Chesney (1999) discuss the concerns related to  
extrapolating childrens’ doses of medications from recommended adult doses.  These 
authors present the problems with this practice as children and adolescents’ bodies are 
different than adults and therefore may metabolize the medication in a different manner.  
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Drug absorption, metabolism, and secretion are different in childrens’ maturing bodies 
than in an adult.  However, pediatricians and other specialists are left with using 
professional judgment when prescribing an approved drug for unapproved purposes (off-
label use).  Therefore, as children and adolescents are being prescribed psychotropic 
medications for which no specific clinical trials demonstrating their efficacy for this age 
group occurs widely, close monitoring of medication response is vital.  Given the 
widespread use of psychotropic medications in children and the paucity of clinical trials 
with this population along with the significant differences in children and adolescents’ 
biological development, close monitoring of medication benefits and side effects is 
needed. Additionally, considering researchers have found many of the reasons children 
are prescribed a psychotropic medication is to treat a symptom of a disorder that 
manifests itself in the school environment, monitoring in this setting is crucial (Connor & 
Barkley, 2006; Mattison, 1999).   The next section of this literature review will document 
the most prevalent childhood mental and behavioral disorders, the most commonly 
prescribed medications, and the potential side-effects of pharmacological treatments on 
academic and social functioning.  
Effects of Psychotropic Medications on Academic, Behavioral, and Social 
Functioning  
The most up-to-date comprehensive review of psychotropic medications and 
effects on academic and social functioning was completed by the American 
Psychological Association (APA) Working Group on Psychoactive Medications for 
Children and Adolescents (2006).  This report includes examinations of risk-benefit ratios 
of pharmacological treatments for the most common childhood disorders treated with 
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psychotropic medications.  The APA Working Group report comprehensively reviewed 
extant literature in selected peer-reviewed journals as well as Food and Drug 
Administration (FDA) safety and efficacy data.  Additionally, psychosocial, 
psychotropic, and combined treatments (i.e., psychosocial and psychotropic treatments) 
were reviewed for evidence of efficacy.  The disorders relevant to this study due to their 
prevalence in child and adolescent populations reviewed by the Working Group include: 
(a) Attention-Deficit/Hyperactivity Disorder (ADHD); (b) Oppositional Defiant Disorder 
(ODD); (c) Conduct Disorder; (CD); (d) Tourette and tic disorders; (e) Obsessive–
Compulsive Disorder (OCD); (f) anxiety disorders; (h) depressive disorders; (i) bipolar 
disorder; (j) schizophrenia; and (k) autism spectrum disorder. The information gleaned 
from the APA Working Group’s review of each aforementioned disorder will focus on 
the effects on academic and social functioning for the purposes of this literature review.  
Table 1. examines in detail both the beneficial and deleterious effects of psychotropic 
medications on academic and social functioning.  The purpose of providing this 
information is to inform the reader of the prevalence of each aforementioned disorder, the 
types of psychotropic medications commonly used to treat each disorder and the side 
effects each medication may have in children and adolescents.   
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Disorder/ 
Prevalence Rates 
Most Common Psychotropic 
Medications Utilized to Treat 
Disorder: 
Evidence of Efficacy in Children 
and Adolescents 
Common Side Effects  
Attention-Deficit/ 
Hyperactivity 
Disorder (ADHD) 
 
Prevalence Rates in 
Children: 5% 
Stimulants: 
Methlyphenidate, a central 
nervous system stimulant 
Nonstimulants: 
Straterra 
Amoxetine (norepinephrine 
reuptake inhibitor) 
Clonidine (antihypertensive) 
 
Stimulant medications: 
Well documented (e.g., MTA 
Cooperative Group, 1999) 
 
Nonstimulants: 
Less evidence of efficacy 
 
Polypharmacological Treatments: 
Little empirical evidence of efficacy, 
regularly used to counteract side-
effects (e.g., insomnia from 
stimulants) and treat co-morbid 
disorders (e.g., oppositional defiant 
disorder) 
 
Stimulant Medication Side Effects: 
Decreased appetite, nausea, chronic headaches sleep 
difficulties, growth problems (Connor & Barkley, 
2006) anxious behaviors,  
Nonstimulant Side Effects: 
Chronic stomachaches, appetite suppression, Food and 
Drug Administration (FDA) “black box” warning of 
suicidal ideation in children under 18 years of age 
(U.S. FDA, 2005) Risk of liver toxicity for amoxetine 
Positive Effects on School Performance (Academic 
and Psychosocial Functioning): 
 Increased attention to task with appropriate 
doses 
 Decreased impulsivity behaviors 
Negative Effects on School Performance (Academic 
and Psychosocial Functioning):  
 Reduced academic engagement due to 
medication side effects (e.g., headaches, 
nausea, anxious symptoms) 
 Behavioral variability related to short half-life 
of medication 
 Lethargy in the school setting associated with 
insomnia from stimulant medications 
Table 1  
Psychotropic Medications by Disorder: Evidence of Efficacy and Side Effects 
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Oppositional 
Defiant Disorder 
(ODD) 
Conduct Disorder 
(CD) 
 
ODD Rates in 
Children: 2-16% 
 
CD Prevalence 
Rates in Children: 
1-10% 
 
 
 
  
Stimulants: 
Methylphenidate 
 
Nonstimulants: 
Atomoxetine 
Clonidine 
 
 
Antipsychotic medications: 
 Halperidol, Risperidone 
 
Lithium 
Stimulant medications: 
Well documented 
 
Nonstimulants: 
Less evidence of efficacy 
 
 
 
Antipsychotic medications: 
Off-label use only  
Stimulant Medication Side Effects: 
Decreased appetite, sleep difficulties, growth problems 
(Connor & Barkley, 2006) anxious behaviors  
Nonstimulant Side Effects: 
Chronic stomachaches, appetite suppression, Food and 
Drug Administration (FDA) “black box” warning of 
suicidal ideation in children under 18 years of age 
(U.S. FDA, 2005),  drowsiness decreasing focus and 
attention leading to reduced academic performance) 
Antipsychotic Medication Side Effects: 
Extrapyrimidal symptoms (permanent) 
Headaches, drowsiness, nausea 
Memory loss, decreased cognitive functioning  
Motor tremors  
 
Positive Effects on School Performance (Academic 
and Psychosocial Functioning): 
 Decreased externalizing symptoms  
 Possibly may increase efficacy of behavioral 
interventions  
 
Negative Effects on School Performance (Academic 
and Psychosocial Functioning):  
 Reduced academic engagement due to 
medication side effects  (e.g., headaches, 
nausea, anxious symptoms) 
 Behavioral variability related to short half-life 
of medication 
 Lethargy in the school setting associated with 
insomnia from stimulant medications 
 Memory loss as a side effect of lithium, 
cognition difficulties 
 Decreased fine motor skills (resulting from 
motor tremors) 
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Tic Disorders 
(Including 
Tourettes 
Syndrome) 
 
 
 
Prevalence Rates in 
Children and 
Adolescents: 2% 
 
 
Alpha 2 agonists 
Clonidine 
Guanfacine 
 
 
 
 
Typical 
Neuroleptics/Antipsychotics 
Halperidol 
Pimozide 
 
Atypical Neuroleptics 
Risperidone 
Ziprazidone 
Atmoxetine 
 
 
Randomized clinical trial data 
available, however extremely small 
sample sizes were employed 
 
 
 
 
Long-term effects unknown on all 
classes of medication in children and 
adolescents 
Alpha 2 agonists 
Sedation, dry mouth, headaches, irritability, dysphoria, 
postural hypotension, Guanfacine is associated with 
less risk of sedation 
 
 
 
 
Typical Neuroleptics 
Sedation, cognitive dulling, akathisia, extrapyrimidal 
symptoms (EPS), risk of tardive dyskinesia, dysphoria 
 
Atypical Neuroleptics 
Sedation, weight gain, EPS, galactorrhea, dysphoria, 
increased risk of hepatoxicity, diabetes mellitus  
 
Positive Effects on School Performance (Academic 
and Psychosocial Functioning): 
 Decreased externalizing symptoms  
 Increases social/emotional functioning by 
decreasing symptoms  
 Possibly may increase efficacy of 
psychosocial interventions 
Negative Effects on School Performance (Academic 
and Psychosocial Functioning): 
 Loss of academic skills due to medication side 
effects (e.g., cognitive dulling) 
 Reduced academic engagement due to 
medication side effects  (e.g., sedation, 
headaches, dysphoria, cognitive dulling, 
lethargy) 
 Decreased fine motor skills (resulting from 
motor tremors) 
 Increased risk of suicidal ideation resulting in 
decreased school functioning (both academic 
engagement and social functioning) associated 
with atmoxetine  
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Obsessive 
Compulsive 
Disorder (OCD) 
 
 
Prevalence Rates in 
Children and 
Adolescents: 0.5-
2.0% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Selective Seratonin Reuptake 
Inhibitors (SSRIs) 
Prozac 
Paxil 
Zoloft 
Celexa  
 
Clomipramine 
Some evidence of efficacy, small 
sample sizes 
 
Long-term effects unknown  
SSRIs 
Nausea, disinhibition, loss of appetite or weight gain, 
sedation, tremors, potential suicidal ideation (FDA 
warning)  
*Must be closely monitored to ensure child or 
adolescent is regularly taking medication, otherwise 
serious withdrawal symptoms can occur 
 
Clomipramine 
Potential cardiotoxicity in children and adolescents 
(used very infrequently), sedation, fainting, seizures, 
tremors, weight gain 
 
Positive Effects on School Performance (Academic 
and Psychosocial Functioning): 
 Decreased  symptoms of disorder  
 Increases social/emotional functioning by 
decreasing symptoms  
 Possibly may increase efficacy of 
psychosocial interventions 
Negative Effects on School Performance (Academic 
and Psychosocial Functioning):  
 Reduced academic engagement due to 
medication side effects  (e.g., headaches, 
nausea, sedation) 
 Disinhibition associated with impulsive 
behaviors  
 Psychosocial difficulties associated with 
weight gain among peers 
 Increased risk of suicidal ideation resulting in 
decreased school functioning (both academic 
engagement and social functioning) 
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Disorder/ 
Prevalence Rates 
Most Common Psychotropic 
Medications Utilized to Treat 
Disorder: 
Evidence of Efficacy in Children 
and Adolescents 
Common Side Effects  
Anxiety Disorders 
(Generalized 
anxiety disorders, 
social anxiety 
disorders, 
separation anxiety 
disorders) 
 
Prevalence Rates in 
Children and 
Adolescents: 12-
20% 
 
 
 
 
Selective Seratonin Reuptake 
Inhibitors (SSRIs) 
Prozac 
Paxil 
Zoloft 
Celexa  
 
Benzodiazapines  
Found to be ineffective for 
children, rarely used in 
adolescents due to habit-
forming dangers 
Some evidence of efficacy, small 
sample sizes 
 
Long-term effects unknown 
SSRIs 
Nausea, disinhibition, loss of appetite or weight gain, 
sedation, tremors, potential suicidal ideation (FDA 
warning) 
*Must be closely monitored to ensure child or 
adolescent is regularly taking medication, otherwise 
serious withdrawal symptoms can occur 
 
Positive Effects on School Performance (Academic 
and Psychosocial Functioning): 
 Decrease of negative symptoms of disorder 
 Increase social interaction  
 Possibly increase effects of psychosocial 
interventions 
Negative Effects on School Performance (Academic 
and Psychosocial Functioning):  
 Reduced academic engagement due to 
medication side effects  (e.g., headaches, 
nausea, sedation) 
 Disinhibition associated with impulsive 
behaviors  
 Psychosocial difficulties associated with 
weight gain among peers 
 Increased risk of suicidal ideation resulting in 
decreased school functioning (both academic 
engagement and social functioning) 
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Depressive 
Disorders 
Prevalence Rates in 
Children and 
Adolescents: Up to 
20% at some point 
during childhood 
through 
adolescence 
 
 
 
 
 
 
 
Selective Seratonin Reuptake 
Inhibitors (SSRIs) 
Prozac 
Paxil 
Zoloft 
Celexa  
 
Tricyclics 
Some evidence of efficacy, small 
sample sizes, more efficacy in 
adolescent populations  
 
Long-term effects unknown 
 
 
 
No efficacy data in school-age 
populations  
SSRIs 
Nausea, disinhibition, loss of appetite or weight gain, 
sedation, tremors, potential suicidal ideation (FDA 
warning) 
*Must be closely monitored to ensure child or 
adolescent is regularly taking medication, otherwise 
serious withdrawal symptoms can occur 
 
 
Tricyclics 
Nausea, cognitive retention difficulties, enuresis 
(daytime and night) blurred vision  
Positive Effects on School Performance (Academic 
and Psychosocial Functioning): 
 Decrease of negative symptoms of disorder 
 Increase social interaction  
 Possibly increase effects of psychosocial 
interventions 
Negative Effects on School Performance (Academic 
and Psychosocial Functioning):  
 Reduced academic engagement due to 
medication side effects  (e.g., headaches, 
nausea, sedation) 
 Disinhibition associated with impulsive 
behaviors  
 Psychosocial difficulties associated with 
weight gain among peers 
 Increased risk of suicidal ideation resulting in 
decreased school functioning (both academic 
engagement and social functioning) 
 
 
Bipolar Disorder 
 
Prevalence Rates in 
Children and 
Adolescents: 1% 
 
Lithium 
 
Valporate 
 
Risperidone 
 
Paucity or randomized controlled 
trials, National Institutes of Mental 
Health is sponsoring medium-size 
study comparing efficacy of lithium, 
valporate, and risperidone in children 
 
Lithium 
Difficulty with memory (e.g., word retrieval) working 
memory deficits, cognitive dulling, weight gain, 
increased risk for Type II diabetes, lipid level 
elevation, transaminase elevation 
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ages 8-14 with bipolar disorder 
 
 
Long-term effects unknown 
 
Valporate 
Change in appetite; constipation; diarrhea; dizziness; 
drowsiness; hair loss; headache; indigestion; nausea; 
stomach pain; trouble sleeping; vomiting; weight 
changes 
Risperidone 
Extrapyramidal effects (sudden, often jerky, 
involuntary motions of the head, neck, arms, body, or 
eyes), dizziness, hyperactivity, tiredness, abdominal 
pain, fatigue, fever and nausea. Orthostatic 
hypotension during the early phase of treatment (drop 
in their blood pressure when rising from a lying 
position and may become dizzy or even lose 
consciousness) 
 
Positive Effects on School Performance (Academic 
and Psychosocial Functioning): 
 Decrease or elimination of negative 
symptoms of disorder 
 Increase social interaction  
 
Negative Effects on School Performance (Academic 
and Psychosocial Functioning):  
 Reduced academic engagement due to 
medication side effects  (e.g., headaches, 
nausea, sedation) 
 Disinhibition associated with impulsive 
behaviors  
 Psychosocial difficulties associated with 
weight gain among peers 
 Increased risk of suicidal ideation resulting in 
decreased school functioning (both academic 
engagement and social functioning) 
 Memory loss as a side effect of lithium, 
cognition difficulties 
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Childhood-Onset 
Schizophrenia  
 
Prevalence Rates in 
Children and 
Adolescents: 0.5% 
(1% onset before 
age nine, 9% before 
age 15) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Typical 
Neuroleptics/Antipsychotics 
Halperidol 
Pimozide 
Risperidone 
Olanzapine 
 
 
 
 
Paucity of data in pediatric 
populations 
 
Long-term effects unknown 
 
Typical Neuroleptics 
Extrapyramidal effects (sudden, often jerky, 
involuntary motions of the head, neck, arms, body, or 
eyes), dizziness, hyperactivity, tiredness, abdominal 
pain, fatigue, fever and nausea. Orthostatic 
hypotension during the early phase of treatment (drop 
in their blood pressure when rising from a lying 
position and may become dizzy or even lose 
consciousness) 
Type II diabetes, difficulty with word retrieval, 
working memory deficits, cognitive dulling 
 
Positive Effects on School Performance (Academic 
and Psychosocial Functioning): 
 Decrease or elimination of negative 
symptoms of disorder 
 Increase social interaction  
Negative Effects on School Performance (Academic 
and Psychosocial Functioning):  
 Reduced academic engagement due to 
medication side effects  (e.g., headaches, 
nausea, sedation) 
 Disinhibition associated with impulsive 
behaviors  
 Psychosocial difficulties associated with 
weight gain among peers 
 Increased risk of suicidal ideation resulting in 
decreased school functioning (both academic 
engagement and social functioning) 
 Memory loss as a side effect of lithium, 
cognition difficulties 
 Effects of orthostatic hypotension (may cause 
dizziness, loss of consciousness) in early 
phases of treatment 
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Disorder/ 
Prevalence Rates 
Most Common Psychotropic 
Medications Utilized to Treat 
Disorder: 
Evidence of Efficacy in Children 
and Adolescents 
Common Side Effects  
Autism Spectrum 
Disorder (ASD) 
 
Prevalence Rates in 
Children and 
Adolescents: 1 in 
150 children and 
adolescents 
33-47% of children with ASD 
are prescribed a psychotropic 
medication* 
SSRIs 
Prozac 
Paxil 
Zoloft 
Celexa  
Alpha 2 agonists 
Clonidine 
Guanfacine 
Atypical Neuroleptics 
Risperidone 
Ziprazidone 
Amoxetine 
Stimulants: 
Methlyphenidate, a central 
nervous system stimulant 
 
Less Common: 
Lithium 
Divalproex Sodium 
 
 
 
 
Limited randomized controlled 
trials utilizing small sample sizes 
 
 
SSRIs 
Nausea, disinhibition, loss of appetite or weight gain, 
sedation, tremors, potential suicidal ideation (FDA 
warning) 
*Must be closely monitored to ensure child or 
adolescent is regularly taking medication, otherwise 
serious withdrawal symptoms can occur 
 
Alpha 2 agonists 
Sedation, dry mouth, headaches, irritability, dysphoria, 
postural hypotension, Guanfacine is associated with 
less risk of sedation 
 
 
Atypical Neuroleptics 
Sedation, weight gain, EPS, galactorrhea, dysphoria, 
increased risk of hepatoxicity, diabetes mellitus  
 
 
Stimulant Medication Side Effects: 
Decreased appetite, chronic headaches sleep 
difficulties, growth problems (Connor & Barkley, 
2006) anxious behaviors 
 
Lithium 
Difficulty with memory (e.g., word retrieval) working 
memory deficits, cognitive dulling, weight gain, 
increased risk for Type II diabetes, lipid level 
elevation, transaminase elevation 
Positive Effects on School Performance (Academic 
and Psychosocial Functioning): 
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 Decreased externalizing symptoms  
 Increases social/emotional functioning by 
decreasing symptoms  
 Possibly may increase efficacy of 
psychosocial interventions 
Negative Effects on School Performance (Academic 
and Psychosocial Functioning):  
 Reduced academic engagement due to 
medication side effects  (e.g., headaches, 
nausea, sedation) 
 Disinhibition associated with impulsive 
behaviors  
 Psychosocial difficulties associated with 
weight gain among peers 
 Lethargy in the school setting associated with 
insomnia from stimulant medications 
 Increased risk of suicidal ideation resulting in 
decreased school functioning (both academic 
engagement and social functioning) 
 Memory loss as a side effect of lithium, 
cognition difficulties 
 Effects of orthostatic hypotension (may cause 
dizziness, loss of consciousness) in early 
phases of treatment 
 Adapted from: APA Working Group on Psychoactive Medications for Children and Adolescents, (2006) 
*(Aman, Lam, & Collier-Crespin, 2003; Aman, Lam, & Van Bourgondien, 2005; Witwer & Lecavalier, 2006). 
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Taken together, the prevalence rates and variety of medications prescribed to 
school-aged children has increased substantially over the past decade.  While the use of 
psychotropic medications in school-aged populations has resulted in positive treatment 
gains for many, there is a paucity of evidence on the effects, particularly long-term 
effects of such pharmacological treatments on children.  Randomized studies are 
currently being conducted to evaluate short and long-term effects of pharmacological 
treatment. However, many children and adolescents have already or currently are 
prescribed medications for which there is little to no scientific evidence of their effects.  
The effects on school performance are even less studied, even as public school personnel 
are asked to play a larger role in the treatment of children with mental health and 
behavioral disorders.   
Legal and Ethical Issues in Medication Utilization in Public Schools  
Researchers report that public school personnel are playing an ever increasing 
role in pharmacological treatment of school-aged children.  Specifically, school personnel 
are increasingly being asked to dispense medications including controlled medications to 
students during the school day.  DuPaul and Carlson (2005) discuss the emerging trend of 
non-medical school personnel (e.g., secretaries and instructional assistants) being asked 
to dispense psychotropic medications including controlled medications with little or no 
supervision. School nursing services are limited in many school systems, particularly in 
rural areas.  As a result, other non-medical school personnel are asked to perform these 
functions which increases the probability of medication administration errors (e.g., lack 
of follow-up to ensure child took his or her medication, overdosing, giving stimulants 
away to other students; DuPaul et al., 2005).   
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The involvement of school personnel in the utilization and administration of 
psychotropic medications is controversial. For example, school personnel are frequently 
the first to recommend treatment including pharmacological agents to treat the symptoms 
of ADHD even before a formal medical diagnosis (dosReis, 2003). While school 
personnel can play a pivotal role in monitoring treatment efficacy as well as side effects 
(DuPaul & Carlson, 2005), both at the federal and state level, legislation has been enacted 
to limit the role of school personnel involvement in the recommendation or requirement 
that a child take a psychotropic medication as a condition of participation in any school 
activity (academic, athletic, or social). Specifically, the reauthorization of IDEA (2004) 
includes provisions for each state to develop policies and practices prohibiting public 
school personnel from recommending parents seek prescriptions for controlled 
substances such as stimulants as a condition for their children to attend school.  
Additionally, the Child Medication Safety Act requires states receiving federal education 
funds to develop specific policies and procedures related to prohibiting school districts 
from requiring a child take a psychotropic medication as a condition of attending school.   
As a result, 23 states have enacted legislation prohibiting school employees from 
recommending psychotropic medication to parents to treat any disorder.  This includes 
the State of Florida (National Conference of State Legislatures, 2004).  In the State of 
Florida Senate Bill 1090, signed into law in 2005, prohibits school personnel (including 
school psychologists) from coercing parents to have their child prescribed a psychotropic 
medication. In addition, the Bill creates safeguards giving parents the right to refuse a 
request by school personnel to conduct a psychological evaluation on their child.  The bill 
also clarifies school personnel’s ability to share information related to emotional and 
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behavioral functioning with parents to allow for information sharing but specifically 
excludes any coercive practices related to pressuring parents to obtain psychotropic 
medications for their child as a condition of attending school (National Conference of 
State Legislatures, 2004).   
While this is obviously a well-intentioned mandate, it also can have negative 
collateral consequences.  For instance, some of the most efficacious treatments for certain 
disorders (e.g., ADHD) include the use of stimulant medications which fall into the 
category of psychotropic medications.  A school psychologist who is well-grounded in 
advocating evidence-based treatments may feel prohibited from recommending that 
parents speak to their physician about an evidence-based treatment for their child out of 
fear of liability.   
As previously discussed, this can have negative consequences for certain school 
employees who are typically charged with evaluating and making recommendations that 
are based on scientific research (e.g., school psychologists).  Given this legislation and 
constraints on school employees (including school psychologists), the next section will 
examine the extant research on medication monitoring practices in public schools.   
Medication Monitoring Practices in Public Schools 
 Guerasko-Moore, DuPaul, and Power (2005) conducted a survey that examined 
medication monitoring practices of school psychologists related to the treatment of 
ADHD.  The survey assessed four areas related to medication monitoring by school 
psychologists specific to children with ADHD.  The areas assessed included (a) the self 
reported use of procedures for monitoring the effects of medications on the symptoms of 
ADHD; (b) training related to medication monitoring; (c) perceptions of effectiveness, 
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acceptance, and feasibility of medication monitoring practices; and (d) perceptions of 
barriers and facilitators related to medication monitoring by school psychologists.  The 
researchers obtained a survey return rate of 64.7% with a total of 437 surveys included in 
analyses.  The demographic data obtained through this survey were aligned with NASP 
membership demographics for the year of the study with respect to age, gender, and 
ethnicity. 
 Guerasko-Moore et al. (2005) found that 54.5% of survey participants reported 
they engaged in medication monitoring as part of their work as a school psychologist.  
Additionally, survey participants who engaged in medication monitoring reported 
monitoring an average of 1-5 students diagnosed with ADHD per year.  Survey 
participants also indicated a relatively strong agreement (3.84 out of 5 on a Likert scale) 
with the statement “monitoring the effects of medication for students with ADHD is a 
role school psychologists should play.”  These findings indicate that while medication 
monitoring is a role that may not be officially required in many school psychologists’ job 
duties, it is one many reported perceiving as important and necessary.  With respect to 
actual practices, the majority of school psychologists who reported engaging in 
medication monitoring for students with ADHD used teacher rating forms, direct 
behavioral observations, and teacher interviews.    
 Perceptions of effectiveness, acceptance, and feasibility of medication monitoring 
practices in addition to actual practices were also assessed. Guerasko-Moore et al. (2005)  
found direct observation, teacher rating forms, and teacher interview were rated as the 
most effective, feasible, and had the highest acceptance for monitoring medications of 
students with ADHD.  Less effective, feasible, and acceptable practices were parent 
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rating forms, parent interview, student interviews, student grades, student self-report 
rating, and curriculum based measurement and assessment practices (CBM/CBA).  
Previous research has found one of the lowest rated methods in the current study, 
CBM/CBA, has significant efficacy when utilized properly (Stoner, Carey, Ikeda, & 
Shinn, 1994).   
 Training in medication monitoring was also assessed in this study.  In line with 
other studies (i.e., Carlson & Demaray, 2001) Gureasko-Moore et al. (2005) found fewer 
individuals indicated they received formal training in medication monitoring (42% of 
study participants) than those who indicated they did not receive formal training (58%).  
The most common methods for training were graduate coursework (14.3%) and 
professional workshops (18.1%).  Examining the differences between the amount of time 
spent engaged in medication monitoring activities and trained versus untrained school 
psychologists, those with training in medication monitoring reported significantly more 
time engaging in this practice for students with ADHD.   
 Perceptions of barriers and facilitators related to medication monitoring by school 
psychologists were rated on a Likert scale ranging from one (significant barrier) to five 
(significant facilitator) in engaging in medication monitoring.  The researchers found 
time was the most significant barrier with accessibility and perceptions of school 
psychologists’ role in medication monitoring by physicians being less significant barriers.  
In terms of facilitators, the highest rating was teacher support while administrative 
support and amount of training were perceived to be the weakest facilitators related to 
medication monitoring.   
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 The results of this study indicate the majority of school psychologists believe 
medication monitoring is an appropriate professional role.  Over half of all respondents 
indicated they are currently involved in medication monitoring for students with ADHD 
to some degree.  The representative sample from which this study was drawn, as well as 
the relatively high return rate, enhances the generalizability of the results of this study to 
school psychologists who are members of the National Association of School 
Psychologists (NASP).    
 This study has several limitations.  Specifically, this study employed self-report 
data that are not cross referenced.  The results of this study cannot take into account the 
misreading of a question or misrepresentation of answers as the survey was anonymous.  
Also, this study utilized only the NASP database.  While the NASP database allows for 
random selection of a representative sample of NASP members, it does not encompass all 
school psychologists currently working in the U.S.  Additionally, the researchers noted 
that not all NASP members update their demographic information to indicate if they 
work in a school or another setting and may have filled out the survey regardless.  This 
study also found some level of discrepancy between overall NASP demographics and 
study demographics related to training and years of experience.  Lastly, this study 
examined medication monitoring limited to students taking medication for ADHD.  As 
this literature review delineates, a multitude of medications are being taken by children 
with ADHD and a number of other disorders.  
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Collaboration between School Personnel and Medical Providers 
 Extant research on collaboration between pediatricians and school personnel 
indicates overall, pediatricians would like more information regarding medication effects 
from school personnel.  Haile-Mariam , Bradley, and Johnson (2002) conducted a survey 
of pediatricians assessing the type and format of information needed from schools to 
assist in the treatment of ADHD.  The researchers obtained a 66% return rate totaling 332 
returned surveys.  Forty five percent of the respondents worked in a group medical 
practice and 59% were in practice over 15 years.  Information related to medication 
monitoring gleaned from this study indicates pediatricians want more information from 
school personnel.  Specifically, regarding information related to medication monitoring 
and treatment effects, 81% of pediatricians indicated they wanted information from 
school personnel such as direct observation of student behavior.  Additionally, 45% of 
surveyed pediatricians indicated they would like information on medication side effects.  
Only 9% of pediatricians reported school personnel providing this information.   
 Collaboration between school personnel and medical providers is the first step in 
effective medication monitoring (Wodrich et al., 1999).  Collaboration between medical 
providers and school personnel enhances the level and continuity of care for children.  
Researchers have identified the school psychologist as a professional uniquely suited for 
collaboration with medical providers such as physicians to enhance the outcomes for 
children prescribed psychotropic medications (Power et al., 1995; Power, DuPaul, 
Shapiro & Parrish, 1998; Wodrich et al., 1999).  The next section of this literature review 
will discuss the unique skills of the school psychologist and how they relate to 
medication monitoring.   
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Role of the School Psychologist  
 Several researchers have advocated for school psychologists’ involvement in the 
ever increasing numbers of children being prescribed psychotropic medications who are 
also attending school.  Specifically, DuPaul and Carlson (2005) advocated for increased 
school psychologist involvement in helping physicians and families make more effective 
decisions regarding the dosage, clinical effects, and side effects of various psychotropic 
medications.  School psychologists’ are in a unique and well-suited position to assist in 
medication monitoring considering the following skills many school psychologists 
possesses: (a) training in data-based decision making; (b) training in systematic problem-
solving examining all factors from an ecological perspective such as the environment, 
specifically the child, the curriculum, and family influences; (c) ability to progress 
monitor using methods sensitive to small changes in performance; and (d) the ability to 
observe children and adolescents in the school environment which typically is 
significantly different from office-based settings or other community settings  (DuPaul & 
Carlson, 2005).  The aforementioned skills school psychologists’ possess enable them to 
engage in medication monitoring as well as collaboration with the prescribing physician 
and the school nurse who may have responsibility to oversee administration of 
medications.  Collaboration between the school nurse and school psychologist can 
harness both professional’s knowledge and skills.  The school nurse is trained in 
administration of medication, common side effects, and adverse reactions while the 
school psychologist brings knowledge of assessment of behavior (the variable medication 
is most often used to affect) as well as collaboration skills to bring together multiple 
professionals from different disciplines.   
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School psychologists possess numerous strengths related to medication 
monitoring.  Specifically, school psychologists are in a unique position to evaluate the 
medication effects within the natural environment (i.e., school environment).   School 
psychologists have specific training utilizing broad and narrow band rating scales, direct 
observation of behavior using narrative recording methods as well as standardized 
behavior rating methods.  For example, the Behavior Observation System in Schools 
(BOSS; Shapiro, 2010) has been found to be efficacious to evaluate medication efficacy 
(Power, DuPaul, Shapiro, & Kazak, 2003).  Also, review of permanent products such as 
the accuracy and completion of assignments are available to school psychologists and 
have been shown to be sensitive to medication effects (Power et al., 2003).  Additionally, 
the use of curriculum based measurement (CBM) has been shown to be an efficacious 
method of determining the response-to-medication for certain disorders such as ADHD 
(Stoner, Carey, Ikeda, & Shinn, 1994).  CBM has been found to be sensitive to changes 
in dosages of methylphenidate to treat symptoms of ADHD (Stoner et al., 1994). School 
psychologists may also assist in determining optimal dosage (DuPaul & Carlson, 2005).  
Psychotropic medications interact differently with each child and dose-response effects 
can vary widely for children.  As a result, determining optimal dosages is essential to 
obtain the greatest medication efficacy (DuPaul et al., 2005).  School psychologists are in 
the unique position to utilize the aforementioned techniques (e.g., CBM and direct 
behavior observations in the school environment) to assist in finding an optimal 
medication dosage for a child.  
The school psychologist can assist in designing and implementing a medication 
trial in collaboration with the child’s physician (DuPaul & Carlson, 2005).  A medication 
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trial will be a temporary trial of a pre-specified dose of a psychotropic medication which 
may or may not be known to those evaluating its effects.  An open trial is one where all 
parties know the dosage and type of medication. Blinded trials call for only certain 
individuals (not involved in evaluating the medication’s efficacy) to know the dosage and 
type.  The overall goal is to identify the most appropriate dosage with the least side 
effects and maximum benefit for the child. Collaboration between the school 
psychologist and other school personnel such as the school nurse with the child’s 
physician is an important aspect of a well designed medication trial (DuPaul & Carlson).   
 Children currently receiving a psychotropic medication may need continual 
progress monitoring to best assess overall efficacy (DuPaul & Carlson, 2005).  Progress 
monitoring in the school environment can prove valuable to a treatment team as seeing a 
child in an office setting may be not indicative of actual functioning within the school 
environment (Pelham et al., 2000).  The level of behaviors occurring in the natural setting 
can provide valuable information to the treatment team, particularly when the information 
is provided by an individual with specific training in assessing and observing behavior 
such as the school psychologist (DuPaul et al., 2005).    
Finding an optimal dosage (least side effects and maximum beneficial effects) for 
children receiving a psychotropic medication is critical to balance to cost and risks of the 
medication (e.g., side effects) to the benefits (e.g., improved functioning).  For example, 
children with ADHD may react differently to the same medication and dose even when 
considering gender, age, and height (DuPaul et al., 2005).  The MTA Cooperative Group 
(1999) which conducted the most comprehensive evaluation of effects of treatments for 
ADHD to-date, found for children with ADHD, dose-response varied considerably across 
 42 
 
children. This was found while holding constant other factors such as gender, age, and 
weight.  The results of a follow-up study by the MTA Cooperative Group (2009) 
recommend a highly individualized medication monitoring plan due to wide ranging 
dose-responses among children (Molina, et al., 2009).   
DuPaul et al. (2005) discussed possible ways for school psychologists to assist in 
determining optimal dosage.  Specifically, the treatment team comprised of the physician, 
parent, teacher, and school psychologist determine keystone behaviors which will serve 
as outcome data.  Keystone behaviors are behaviors which if affected will also have 
collateral effects on other areas of functioning.  For example, the researchers list possible 
keystone behaviors such as accuracy of completed assignments along with reductions in 
disruptive behavior in the classroom.  After the team has agreed upon keystone behaviors 
to monitor, the school psychologist can assist in collecting assessment data to help 
determine the lowest efficacious dosage.    
Wodrich and Landau (1999) also advocate for an increased role of the school 
psychologist in collaboration between medical and school entities including monitoring 
of medications.  Specifically, the authors state that school psychologists are in a unique 
position to assist in contributing to effective outcomes for children with medical 
conditions who may be prescribed a psychotropic medication.   Wodrich et al. (1999) 
recommend strategic partnerships between school psychologists and local pediatricians 
for a variety of reasons.  One of the most compelling reasons the authors cite is the school 
psychologist’s access to children in the natural environment.  DuPaul et al. (2005) also 
state access to the natural environment as well as school psychologists’ possessing the 
requisite knowledge and skills to effectively monitor medications make this school 
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professional uniquely suited for this practice. Wodrich et al. (1999) recommend building 
a working relationship between primary care pediatrics and school psychologists, 
particularly for children with involved medical concerns.  The authors also recommend 
school psychologists and pediatricians forge working alliances for school-age children 
taking medications that may impact academic as well as social-emotional functioning.  
Sulkowski, Jordan, and Nguyen (2009) also advocate for increasing collaboration 
between physicians prescribing psychotropic medications and school psychologists.  The 
authors present numerous strategies aimed at decreasing barriers and increasing 
opportunities for collaboration.  Specifically, Sulkowski et al. describe using guidelines 
set for by the American Academy of Child and Adolescent Psychiatry (2004) to support 
collaborative efforts and avoid role confusion.  The authors advocate for school 
psychologists to assist the prescribing physician in better understanding school systems 
and becoming more informed about the school environment and specific adaptations that 
can be made (e.g., lower task demands, assign a peer helper). Also, the authors advocate 
for school psychologists taking leadership roles in their school systems by creating 
district-wide consultation roles with local pediatricians and other physicians (e.g., child 
and adolescent psychiatrists).  Additionally, Sulkowski et al. advocate forging alliances 
with physicians to promote district-wide services such as providing pharmacological 
consultations and in-service trainings on psychotropic medication management.  By 
utilizing a district-wide approach, resources of the consulting physician and the school 
psychologist can be more efficiently utilized. 
Given these recommendations on forging collaborative partnerships, research has 
found physicians are open and willing to collaborate with school personnel; particularly 
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school psychologists on issues related to medications children are receiving (Ax, 
Bradley-Klug, & Scott, 2003; Barnett, Duncan, & O’Connors, 1999).  However, in 
general, physicians were unsure of how to collaborate (e.g., who to contact within the 
school system; Ax et al., 2003).  Other researchers have found physicians attempted to 
collaborate first with the school nurse and classroom teacher while 40% reported 
attempting to collaborate with the school psychologist (Bradley-Klug, Sundman, Nadeau, 
Cunningham, & Ogg, 2010).   The extant research on this topic is limited by only the 
aforementioned studies as well as small to medium sample sizes reported.  Therefore, the 
information gleaned from each study cannot be generalized across all physicians.     
 Although medication monitoring is a practice school psychologists may be 
equipped to assist in and medical providers indicate they would like this information, 
there are ethical considerations that must be taken into account.   Specifically, legislation 
previously mentioned may prohibit a school psychologist from recommending an 
efficacious treatment for a child because that treatment may involve the use of a 
psychotropic medication.  For example, Carlson, Thaler, and Hirsch (2005) discuss an 
example where a research-supported efficacious treatment for ADHD involves a multi-
modal approach that can include the use of a stimulant medication which falls under the 
class of psychotropic medications.  A school psychologist may feel hesitant to discuss 
with parents all approaches due to fear of liability or noncompliance with educational 
law.  Carlson and colleagues (2005) propose ethical considerations school psychologists 
should take into consideration when engaging in medication monitoring.  Carlson and 
colleagues advocate utilization of a problem-solving model to take into consideration all 
variables and possible outcomes as an important step for school psychologists who 
 45 
 
engage in medication monitoring.  A problem-solving approach leads to a balance 
between acting in the best interests of the child, utilizing evidence-based treatment 
approaches, and following district/state policies related to medications.   
 Research examining school psychologists’ knowledge and training related to 
psychopharmacology and medication monitoring is lacking.  However, research indicates 
school psychologists are routinely involved in consultation (e.g., member of school-based 
problem-solving team, involved in evaluations for special education services) where 
medications are being utilized.  School psychologists may also be suited to collaborate 
with the child, his or her parents, and the prescribing physician to implement a behavioral 
plan to increase adherence to medication regimens if this is a problem for a child or 
adolescent.  Research has found adherence to medication regimens occurs due to a 
myriad of factors such as intolerable side effects and misunderstanding of the need to 
regularly take medication (Bussing, Koro-Ljungberg, & Gary, 2005; Gau, Chen, & 
Chow, 2008).  
 Carlson, Demaray, and Hunter-Oehmke (2006) conducted a survey examining 
school psychologists caseloads in which students were receiving medications, types of 
training related to pharmacology, and consultative efforts monitoring medications.  A 
national sample of 320 school psychologists who were members of NASP was utilized in 
the analyses. A 37% return rate was reported. Demographic data obtained in the survey 
indicated the sample was consistent with NASP membership with respect to gender, 
ethnicity, type of degree, and years of experience.  The findings indicated 63% of school 
psychologists were involved in medication evaluation trials in the past year.  Also, in 
nearly a quarter of cases school psychologists were involved, the children were receiving 
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psychotropic medication as part of an intervention.  Additional findings included the 
majority of school psychologists have not had formal university training in child 
psychopharmacology (81%) and the primary method school psychologists acquired 
background knowledge in child psychopharmacology was through professional 
workshops (88%), and independent reading (96%).  The depth and comprehensiveness of 
the workshop training was not delineated in the survey.  Approximately 62% of school 
psychologists reported working with physicians and parents to evaluate medication trials 
for children, but collaborative monitoring was infrequent. Additionally, these instances 
were limited to treatment of ADHD.   
 The strengths of this study include being the only known survey to assess 
medication monitoring and child psychopharmacology among school psychologists.  The 
researchers highlighted important information, particularly with respect to the number of 
cases on which school psychologists are consulting that include medication monitoring.  
Limitations of this study include a relatively small return rate (34%), potentially 
lessening the degree to which one can make confident conclusions about the overall 
prevalence of medication monitoring practices and overall conclusions based on the 
survey.  Additionally, while simple and straightforward to read, the survey could have 
gleaned more information from respondents that would be valuable.  For instance, 63% 
of respondents indicated they collaborate with physicians, but no information was 
provided about what practices were used when evaluating pharmacological interventions. 
Nevertheless, this survey is the only examination of both school psychologists’ 
knowledge and training in child psychopharmacology and medication monitoring 
practices.   
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Conclusions  
Current research indicates the utilization rates of psychotropic medications 
prescribed to school-age children has remained relatively stable to treat some disorders 
(i.e., ADHD) while the utilization rates of psychotropic medications  used to treat other 
disorders (e.g., depression, autism, Aspergers syndrome, and ODD/CD) have increased 
dramatically over the past decade (Abrams, Flood, & Phelps, 2006).  Many of the current 
psychotropic medications being used in pediatric populations have no randomized 
controlled trials demonstrating their efficacy in this population. As a result, the vast 
majority of psychotropic medications are approved for use in adults but are prescribed 
off-label to children. Thus in many cases, the side-effects and long-term effects on 
academic and social-emotional functioning in children have not been studied and can 
vary dramatically between children due to different rates medications are metabolized.  
Many of the medications being utilized in pediatric populations have both positive and 
negative possible effects on school performance.  Some effects are directly linked to 
academic performance (e.g., memory loss, cognitive dulling) which may go unnoticed by 
other school personnel without training in assessment and progress monitoring.   
Children spend a majority of their waking hours in the school environment. The 
psychotropic medications are in many cases prescribed to treat problem behaviors that are 
occurring in the school environment as school personnel has been found to be one of the 
first to suggest the need for medication dosReis et al. (2003).  School psychologists are in 
a unique position to assist in medication monitoring due to specialized training in 
progress monitoring, assessment of behavior, collaboration and consultation skills, and 
training in systematic problem-solving. 
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 There are significant gaps in the literature regarding the practices and prevalence 
of medication monitoring beyond students taking medication for ADHD.   Additionally, 
no research to date has examined the acceptability and feasibility of monitoring 
medications beyond those for ADHD. Prevalence rates suggest significant amounts of 
children and adolescents may be coming to school taking psychotropic medications for 
other disorders (e.g., challenging behavior, anxiety and/or depressive symptoms).  
Additionally, research has not yet examined the degree to which school personnel are 
informed about a child who is taking a psychotropic medication so that an individual can 
assist in monitoring its effects in the school environment.  Given the variety of 
psychotropic medications children are currently receiving, the lack of efficacy studies of 
the use of psychotropic medications in children examining short-term and long-term 
effects, potential serious side-effects (e.g., suicidal ideation) more research is needed.  
This is particularly important as more children and adolescents are prescribed 
psychotropic medications for which a paucity of efficacy research is available.  Side 
effects, interaction effects from multiple medications being utilized (polypharmacy) can 
cause acute reactions that may at best impede academic performance and at worst cause 
serious side effects (e.g., extra pyramidal symptoms, suicidal behavior).  The current 
study addresses these gaps in the literature.   
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Chapter Three 
Method 
Introduction 
 This chapter describes the methods used to collect data for the study.  The 
following facets of the study will be described in this order: (a) participants; (b) 
respondent information, (c) demographic information; (d) materials used in the study, and 
(e) procedures. 
Participants 
Participants for this study consisted of a sample of practicing school psychologists 
from the 2010-2011 Florida Association of School Psychologists (FASP) membership 
directory.  Currently, there are approximately 500 members listed as active in the 
directory.  School psychologists who are not currently working in public schools or who 
are not currently working in a practitioner capacity (e.g., retired or not working in a 
school setting) were removed from the sample resulting in a total sample of 273 potential 
respondents.  
Survey studies have examined school psychologists’ diagnostic practices and 
beliefs related to medication monitoring and/or knowledge of child psychopharmacology.  
The researchers conducting these studies have obtained a usable response rate ranging 
from 37% (Carlson, Demeray, & Hunter, 2006) to 64.7% (Guereasko-Moore, DuPaul, & 
Power, 2005).  Given the wide variation in response rates across similar studies the goal 
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for this study was to obtain a usable response rate of at least 50% with a minimum 
response rate of 35%.  As a result, surveys were mailed to the entire sample listed as 
currently working in a school setting.   A 50% return rate would then yield 136 returned 
surveys.  In order to arrive at this specific number of surveys, a power analysis was 
conducted utilizing Cohen’s (1988) statistical formula.  A minimum return rate of 35% 
yielding 96 surveys would result in adequate power (> .80).   
Respondent Information 
 The number of respondents for this study and percentage of the total sample are 
presented in Table 2. A total of 166 of the 273 potential respondents replied to either the 
first or second mailing, resulting in a return rate of 61%.  A total of 26 respondents 
checked a box at the beginning of the survey indicating they did not currently work in a 
school and returned the blank questionnaire.   
 The response rate for the first mailing was significantly higher than the rate for 
the second mailing.  Specifically, 134 out of 273 respondents returned the questionnaire 
after the first mailing.  The researcher utilized specific numeric codes on the outside of 
each return envelope in order to determine if the respondent was mailing back the 
questionnaire from the first or second mailing.  This represented a 49% response rate for 
the first mailing.  For participants sent a second questionnaire, 32 out of 139 initial non-
responders returned a questionnaire.  This represented a 23% response rate for the second 
mailing.   
 A total sample of 166 questionnaires and 140 useable surveys (i.e., participants 
indicating they did not work in a school were excluded from analyses) was considered 
within the acceptable range for the analyses in order to answer each research question.  
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The power achieved for this sample was calculated to be adequate (> .80) based on 
Cohen’s (1988) statistical formula.  Additionally, when comparing response rates for the 
current study to previous research the overall response rate is within the range of other 
empirical studies.  
Table 2 
Respondent Data  
 
Item  
 
n % of Total Sample 
Total questionnaires sent-1st mailing  273 100% 
Total questionnaires returned-1st mailing 134 49% 
Total questionnaires sent -2nd mailing  139 51% 
Total questionnaires returned-2nd mailing  32 23% 
 Total of respondents not eligible  26 9.5% 
 Total number of non-responders  107 39% 
Total useable questionnaires  140 51% 
Total returned surveys (including ineligible) 166 61% 
 
Demographic Information 
Demographic information was collected from all respondents in addition to 
questions regarding types of degrees held outside the field of school psychology, years 
practicing, student to school psychologist ratio, and percentage of time working with 
various K-12 grade levels including time spent in non-student activities (e.g., district 
office).  A summary of demographic information collected is presented in Table 3. The 
majority of the sample was female (84.3%).  The ethnicity of the sample was largely 
White, not of Hispanic origin (81.4%).  The sample closely represents the demographic 
information collected by the National Association of School Psychologists (NASP; 2010) 
with some noteworthy exceptions. Specifically, in the study sample 81.5% of respondents 
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indicated holding a specialist or master’s +30 degree whereas in the NASP sample this 
value was 45.76%.  Additionally, in the study sample the reported school psychologist to 
student ratios are significantly higher.  Respondents indicated 38.9% had a school 
psychologist to student ratio of 1: >3,000 compared to only 4% in the NASP sample. 
  Given that the sample was selected from members of the Florida Association of 
School Psychologists, the entire sample reported practicing in the State of Florida. The 
vast majority of respondents reported working full-time (95%) while 0.7% reported part-
time employment, 2.1% reported employment as a contractual/independent consultant, 
and 2.1% did not respond to this question.  Regarding degree level, the majority of 
respondents (81.5%) reported holding a specialist or master’s +30 degree in school 
psychology while 14.3% reported holding a doctorate.  A lesser percentage reported 
holding a master’s degree only (4.3%).  A question was included in the survey regarding 
graduate degrees held in fields outside school psychology.  Approximately 14% of 
respondents listed degrees held in clinical psychology, counseling psychology, special 
education, educational leadership, and other fields such as information technology.  All 
respondents reported holding master’s degrees in other fields with the exception of one 
respondent reporting a doctorate in educational leadership.  
Examining the years of experience of respondents revealed most respondents had 
greater than six years of experience practicing as a school psychologist.  Specifically, 
89.3% of respondents had more than 10 years experience practicing as a school 
psychologist while only 10.7% reported less than five years in practice.  The school 
psychologist to student ratio varied greatly across respondents.  The lowest school 
psychologist to student ratio reported was 1:450 while the highest was 1:8,500.  The 
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mean school psychologist to student ratio was 1:2,092.  Respondents were asked to 
indicate their primary geographic setting in which they work (i.e., urban, suburban, or 
rural).  Respondents indicated 25% working in an urban, 49.3% in suburban, and 25.7% 
in rural locations.  Regarding the population of students served, responses varied.  The 
most frequent work setting was elementary school (56.5%), followed by middle school 
(17.5%), and high school (15.3%).  Some respondents reported working in a Pre-K 
setting (8.5%) for some portion of their time while others reported working in a non-
student allocation such as being assigned to the district office (2.2%) for part of their 
time.  One respondent indicated working full-time in a non-student allocation. As a result, 
the data from that respondent were excluded in analyses due to no direct student contact 
being reported.  The demographic characteristics of the sample compared to the 
information provided by NASP are displayed in Table 3.   
Table 3 
Comparison of School Psychologists’ Demographic Categories of Current Study to NASP 
Membership (2010) 
 
 
Demographic Information  
Current Study 
n = 140 
NASP (2010) 
n = 1272 
Gender   
      Male 15.7% 21.9 
      Female 84.3% 78.1 
 Ethnicity    
Black/African American 8.6% 3% 
Asian American/Pacific Islander 1.4% 1.3% 
Native American/Alaskan Native 0% .6% 
White/Caucasian 81.4% 90.7% 
Hispanic/Latino 8.6% 3.4% 
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Other 0% 1% 
Highest Degree in School Psychology   
Bachelor’s 0% 0% 
Master’s  4.3% 25.06% 
Master’s +30/Specialist 81.5% 45.76% 
Doctorate 14.3% 24.17% 
Years Practicing as a School Psychologist   
0-5 years 10.7% 30.3% 
6-10 years 20% 15.9% 
11-15 years 31.4% 14.3% 
16+ years 37.9% 27.6% 
School Psychologist to Student Ratio   
<1000:1 22.1% 43.6% 
<1500:1 23.7% 67.9% 
>2000:1 15.3% 14.4% 
>3000:1 38.9% 4.0% 
Primary Work Location    
Urban 25% 25.6% 
Suburban 49.3% 43.4% 
Rural 25.7% 24.0% 
 
 
Materials 
 A cover letter, included with the survey, presented the purpose of the study, 
estimated time to complete the survey, provided the principal investigator’s (PI) contact 
information, and an explanation of the incentives for completion of the survey were 
included with the survey (Appendix A).   Specifically, in order to increase the response 
rate, each respondent received a U.S. currency one dollar bill enclosed in the survey as an 
incentive to return a completed survey.  Previous research demonstrates that offering an 
upfront incentive for completing a survey increases the useable response rate (Dillman, 
Smyth, & Christian, 2009; Erwin & Wheelright, 2002; Tuten, Galesic, & Bosnjak, 2004).   
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The survey (see Appendix C) included a section requesting demographic 
information along with Likert-type rating scales.  Participants were asked to provide 
demographic data including their gender, ethnicity, job status (i.e., full-time, part-time, 
contractual), highest degree in school psychology, highest degree earned not in school 
psychology, number of years practicing as a school psychologist, type of schools served, 
student to school psychologist ratio, and percentage of time working with students at 
different grade levels.  Following the demographic section, the survey was divided into 
five primary areas of school psychologists’ practices related to medication monitoring 
and beliefs of effectiveness, efficacy, and feasibility of methods used to monitor 
medications. Specifically, the survey assessed (a) the self-reported training related to 
medication monitoring, (b) the types of disorders students are diagnosed with for which 
school psychologists are monitoring medications, (c) the procedures utilized to monitor 
the effects of medications, (d) the effectiveness, acceptability, and feasibility of 
medication monitoring procedures, and (e) facilitators and barriers to monitoring 
medications in schools.     
 Participants were asked a variety of “yes/no”, Likert type and frequency of use 
questions to gather data. Participants were asked whether they have been involved in 
monitoring the effects of medications for a student with whom they work.  If the 
participants answered “yes”, they were directed to continue answering several in-depth 
questions assessing the types of disorders for which the school psychologist was 
monitoring medications, and the procedures utilized to monitor medications.  All 
participants were asked to indicate their perceptions related to the degree to which 
various methods of monitoring medications are effective, acceptable, and feasible in the 
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school setting.  All participants were asked to indicate their perceptions related to the 
degree to which various variables are facilitators and barriers to monitoring medications 
in school settings.  The estimated time to complete the survey was between 15-20 
minutes.  
Procedures 
 The first step in conducting this study was to develop the survey itself.  The 
investigator reviewed the extant literature related to this topic to determine gaps in the 
current literature and areas in need of further research.  Specifically, as stated in  
the literature review, one known study has examined school psychologists’ current 
practices related to medication monitoring (Guerasko-Moore & DuPaul, 2005).  
However, that study was limited to examining medication monitoring practices related to 
Attention- Deficit/Hyperactivity Disorder (ADHD) and medications prescribed to treat 
the symptoms of ADHD.  In developing the current survey, the researcher examined 
surveys utilized in previous studies on this topic.  The researcher built on previous 
research and expanded the scope of medication monitoring practices to all psychotropic 
medications that are prescribed to school-age children and adolescents.  The final survey 
consisted of 22 questions, divided into four sections.  Each section utilized fill in the 
blank, multiple choice, and Likert-type question formats to gather data.  The first section 
contains 11 questions related to gender, age, ethnicity, professional background, state in 
which the psychologist is currently employed, employment setting, employment type 
(i.e., part or full-time, contractual), types of students with whom the school psychologist 
works (i.e., grade levels), and the school psychologist to student ratio.  Additionally, at 
the beginning of the survey, respondents who did not work in schools at all were asked to 
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check a box indicating this and return the survey in the postage-paid envelope. The 
second section consisted of questions related to previous training in medication 
monitoring, philosophy of graduate training program, frequency of medication 
monitoring, and types of medications monitored.  To ensure clarity, operational 
definitions were given for overall philosophy of graduate training programs broken down 
into four categories. Each category ranged from extremely traditional (e.g., primary focus 
is on psychoeducational assessment for eligibility in special education programs) to 
extremely non-traditional (e.g., primary focus is on linking assessment to intervention 
and little focus on psychoeducational assessment solely for eligibility in special education 
programs).  The third section consisted of questions related to the types of methods 
utilized to monitor medications.  To collect data on the frequency and number of students 
a school psychologist monitors per year, respondents selected from numeric ranges. To 
collect data on the types of medications school psychologists are monitoring, a 
comprehensive list of psychotropic drug categories was presented.  The fourth section 
consisted of questions assessing specific procedures school psychologists use to collect 
medication monitoring data as well as with whom and the frequency in which the 
information is shared.  Additionally this section assessed perceived facilitators and 
barriers to engaging in medication monitoring.  
Numerous drafts of the survey were reviewed by an expert panel consisting of 
school psychology faculty members with expertise in pediatric school psychology, 
graduate students with experience in conducting surveys, and a faculty member with 
expertise in measurement and survey development.  Based upon the feedback from this 
panel, revisions were made to the survey with respect to clarity of the questions and 
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response options, as well as overall organization of the survey contents.  Specifically, a 
number of changes were made to the survey itself based on recommendations from the 
panel. The length of the survey was shorted from 26 to 22 questions and the format of 
questions was changed from forced choice response type questions to an open-ended item 
for question 22 that asked respondents about facilitators to medication monitoring.  The 
reason for this was to counterbalance question 21 which asked about barriers to 
medication monitoring and respondents were asked to select from a list which they felt 
were barriers. It was hypothesized by the panel and researcher that extant research has 
identified barriers school psychologists face in practice but a paucity of data exists on 
what facets facilitate medication monitoring.  Operational definitions were given at key 
points in the survey to help ensure participants understood how medication monitoring is 
being defined in this study to ensure accurate results.  In section 1 (background 
information), a question (item 6) was added based on a recommendation from a panel 
member  to ask participants about their highest graduate degree earned that was not in 
school psychology.  This question was added based on information gathered during the 
previous NASP membership survey which also added that question to ascertain what 
other degrees school psychologists possess.  The cover letters were also modified in 
several ways to help ensure clarity and to increase the potential response rate by 
shortening the letter(s).  Specifically, the panel recommended a more clear definition of 
medication monitoring in the first paragraph of both the initial and follow-up letters as 
well as attempting to keep the letter to one page in length.   
The next step in the survey development process was to conduct a pilot study of 
the cover letter and survey with 26 practicing school psychologists to gather additional 
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feedback on survey organization and clarity. In addition, seven of those practicing school 
psychologists were randomly selected to be contacted by phone and interviewed about 
the clarity of questions on the survey.  They also were asked how they would answer 
each question to ascertain whether the questions would glean the anticipated information.  
The researcher spent approximately 20 to 30 minutes with each participant going through 
the survey and asking them how they would answer questions.  Overall, the answers 
school psychologists gave were consistent with the data the researcher desired to collect.  
In addition, participants in the pilot study were asked to record the total number of 
minutes required to complete the survey. Participants estimated the total time to complete 
the survey was between 15-20 minutes.  Feedback obtained from participants in the pilot 
study was used to finalize the survey and cover letter.  A number of specific changes 
were made to both the survey and cover letters based on feedback from the panel of 
practicing school psychologists.  Specifically, three of the seven school psychologists 
being interviewed by phone consistently appeared to misunderstand one item.  In item 21, 
which queries respondents regarding barriers to medication monitoring, participants 
appeared confused by the meaning of “lack of community support”.  As a result, the 
researcher added “e.g., collaborative relationships with mental/physical health providers 
in the community” based on feedback from members of the panel.  In item 10 which asks 
“primary location of current work site (please choose one)” several members of the panel 
recommended bolding and placing in italics the word “one” so that respondents would 
only check a single box.  Members of the panel of practicing school psychologists also 
had various formatting recommendations including bolding and increasing the font size 
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of directions to skip items (i.e., item 12) if the question did not pertain to them (e.g., 
respondent has no medication monitoring training).  
Approval to conduct the study was obtained from the University of South Florida 
(USF) Institutional Review Board (IRB) prior to commencement of data collection. This 
assisted in ensuring that all possible and necessary precautions were taken to protect 
human research participants. Once approval was obtained from the USF IRB, approval 
from the Florida Association of School Psychologists (FASP) was obtained.  A separate 
application detailing the scope and nature of the proposed study, research questions, and 
risks versus benefits to participants was provided to FASP. Upon approval from FASP, 
the researcher obtained the FASP membership directory of practicing school 
psychologists via an electronic database of mailing addresses for each participant. Two 
separate mailings were conducted to ensure the highest return rate possible.  Specifically, 
all selected participants were included in an initial mailing that included a cover letter 
(Appendix A), survey (Appendix C), U.S. currency dollar bill (for an incentive), and a 
self-addressed postage-paid envelope.  A unique code number was utilized on the front of 
each survey in order to determine if a participant needed to be mailed a second survey for 
non-response to the first one.   After the first mailing, participants who had not responded 
within one month of the initial mailing were mailed a second survey as well as a follow-
up cover letter (Appendix B) encouraging them to return their completed survey.   
 A database was created using Microsoft Excel in order to enter data as surveys 
were received.  The primary researcher set up the database and developed specific codes 
for entering each item from the survey.  Specifically, each item on the survey was coded 
with a specific number to indicate the respondent’s answer to a question.  The data were 
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then entered by the primary researcher.  Once all data had been entered, every tenth 
survey was checked for errors with a member of the research team.  If an error was 
found, the survey entered prior to and after the randomly selected survey was also 
checked for errors.  All errors were recorded in a separate error log in order to report the 
results.  If an incomplete survey was received, the researcher examined the survey and 
determined if it should be entered into the database.  The  researcher utilized the 
following criteria in order to make the determination whether or not to enter the 
incomplete survey data: (a) if the demographic data were  incomplete the survey was 
excluded from the database as many of the analyses required the combination of answers 
to questions in sections II-IV as well as demographic data, (b) if the demographic data 
were complete and portions of sections II-IV were incomplete, the primary researcher 
made a determination whether to enter the incomplete survey into the database based on 
the amount of information missing.  Specifically, the researcher used his judgment 
whether the survey would provide additional information in the data set or if too much 
information was missing to contribute to the overall study.  This occurred in one instance.  
The respondent left multiple areas of the survey blank including questions related to 
training in medication monitoring as well as their perceptions of barriers and facilitators.  
As a result, due to the necessity of the missing information in order to carry out analyses, 
that respondent’s survey was not included in the data set.     
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Chapter Four 
  
Results 
 
 This chapter begins with a discussion of how the survey data were entered into the 
database and the precautions taken to ensure the integrity of these data.    Each research 
question is then presented along with the specific analyses conducted to address the 
questions. 
Treatment of the Data 
 
 All data were initially entered into a Microsoft Excel spreadsheet during the Fall 
of 2011 by the researcher.  Data were then checked by another member of the research 
team for data entry errors.  Specifically, data were analyzed using the Statistical Package 
for the Social Sciences (SPSS) Version 19 (SPSS Inc., 2010) for values falling outside 
expected ranges following data entry.  If a value was found to be outside the expected 
range, the survey was checked and the correct response entered into the dataset.  Next, 
the researcher and a member of the research team reviewed every tenth survey manually 
to check for data entry errors.  If an error was found the surveys before and after were 
also checked for data entry errors.  At the conclusion of the process 24% of the surveys 
were reviewed for data entry errors.  Data entry errors were calculated to have occurred 
on 0.5% of the surveys checked.  The small amounts of errors found were then manually 
corrected in the Excel spreadsheet.  SPSS was used to conduct analyses in order to 
address each research question.   
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Research Question 1: Do school psychologists believe medication monitoring is a 
role in which they should be engaged?   
 For the purpose of this study, the survey instrument defined medication 
monitoring as follows: “Medication monitoring is defined as including the following 
activities (not an exhaustive list): Consultation with classroom teacher(s) and 
paraprofessionals, utilization of behavior rating scales, behavior observations, review of 
work samples or curriculum-based assessments”.   This definition was provided in bold 
face type to respondents on the second page of the survey prior to being asked questions 
related to medication monitoring.   To address this research question, the frequencies of 
responses to question 14 on the survey instrument were examined.  Specifically, question 
14 asked “Please indicate your opinion to this statement: Monitoring the effects of 
psychotropic medications for students with emotional and behavior disorders (e.g., 
ADHD, depression, anxiety) and other disorders is a role in which school psychologists 
should be involved”.  Respondents could select any one of the following responses to this 
question:  “Strongly Disagree”, “Disagree”, Neither Agree nor Disagree”, “Agree”, and 
“Strongly Agree”.  Descriptive statistics are presented in Table 4 and the percentages 
respondents endorsed by category (e.g., Strongly Disagree, Strongly Agree) are presented 
in Table 5.  Overall, the majority of respondents (74.3%) indicated they “Agree” or 
“Strongly Agree” that medication monitoring is an appropriate role for school 
psychologists.    
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Table 4 
Descriptive Statistics of School Psychologists’ Beliefs Related to Medication Monitoring 
(n =140) 
 n M   95% CI SD Sk Ku Range 
Medication Monitoring 
Agreement 
140 3.93 
 
3.79-4.07 0.85 -0.78 0.95 1-5 
 
Note. The scale of the medication monitoring agreement variable is as follows:  1=Strongly Disagree, 2= 
Disagree, 3= Neither Agree nor Disagree, 4= Agree, 5= Strongly Agree.  
 
Table 5 
Response to Role of School Psychologists in Medication Monitoring (n =140) 
Rating  n Percent 
Strongly Agree  35 25% 
 
Agree 69  49.3% 
 
Neither Agree or Disagree 29  20.7% 
 
Disagree 5 3.6% 
 
Strongly Disagree 2 1.4% 
 
Research Question 2: What is the relationship between school psychologists’ beliefs 
regarding medication monitoring as part of their role and their likelihood of 
engaging in medication monitoring in practice? 
   In order to analyze data pertaining to this question, respondents’ answers to 
survey questions 14 and 16 were examined. Specifically, respondents were asked in 
question 14 to indicate their opinion to the following statement: “Monitoring the effects 
of psychotropic medications for students with emotional and behavior disorders (e.g., 
ADHD, depression, anxiety) and other disorders is a role in which school psychologists 
should be involved”.  A Likert type scale ranging from “Strongly Disagree” to “Strongly 
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Agree” was utilized.   For survey question 16, respondents were asked the following: 
“How frequently do you monitor the effects (beneficial or negative) of a psychotropic 
medication for students with whom you work?”  Response choices for this question were 
“Annually, “Quarterly (i.e., fall, winter, spring)”, “Once per month”, “Once per week”, 
“Daily”, “2-5 times per day”, and “5+ times per day”.   Participants were also directed to 
review the operational definition of medication monitoring provided at the beginning of 
the survey in order to answer this question.   
 In order to address this research question a Spearman rank order correlation 
coefficient was calculated for data collected in questions 14 and 16 on the survey.  The 
data collected from question 14 based on a five-point Likert scale was utilized in the 
analysis.  Specifically, all respondents’ data were used (i.e., respondents who chose 
“Strongly Disagree”, “Disagree”, Neither Agree nor Disagree”, “Agree”, and “Strongly 
Agree”).  Also, the data collected from item 16 was also utilized (i.e., “Annually, 
“Quarterly (i.e., fall, winter, spring)”, “Once per month”, “Once per week”, “Daily”, “2-5 
times per day”, and “5+ times per day”) in the analysis.   Due to the nature of the 
variables, (i.e., ordinal data) the Spearman method was chosen to carry out the analyses.   
The results are presented in Table 6.  Overall, there is a relatively weak relationship 
between respondents’ beliefs related to medication monitoring and frequency of 
medication monitoring.  This not surprising as many respondents reported believing that 
medication monitoring is a role they agree with, yet had not engaged in.   
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Table 6 
Spearman’s Rho Correlation between Beliefs in Medication Monitoring and Actual 
Reported Practices (n = 77) 
 
Variables 1. 2. 
1. Medication monitoring beliefs −  
2. Frequency of medication monitoring practices      0.24* − 
M 2.91 
SD 
          1.02 
 
Note. The scale of the variable “Medication monitoring beliefs” was assessed using the following: 
1=Strongly Disagree, 2=Disagree, 3=Neither Agree nor Disagree, 4=Agree, 5=Strongly Agree.  The scale 
for the variable “Frequency of medication monitoring practices” was assessed using the following: 
1=Annually, 2= Quarterly, 3= Once per month, 4=Once per week, 5 = Daily, 6= 2-5 times per day, 7 = 5+ 
times per day.  
*p < .05.   
In order to further analyze data pertaining to this research question, respondents’ 
answers to survey questions 14 and 15 were also examined.  In question 14, respondents 
were asked to indicate using a five-point Likert scale, their opinion on whether 
medication monitoring is a role in which school psychologists should be involved.  For 
survey question 15, respondents were asked to indicate “yes” or “no” to the following 
question: “Have you been involved in monitoring the effects (beneficial or negative) of a 
psychotropic medication in any manner for a student with whom you work?”  
Respondents were also directed to review the definition of medication monitoring in the 
beginning of the survey before answering question 15.  
 An independent samples t-test was conducted to compare group means for 
respondents who reported being involved in medication monitoring practices (Item #15) 
and their beliefs regarding medication monitoring (Item # 14).  The results are presented 
in Table 7.  There was a significant difference between respondents who endorsed “yes” 
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(M = 4.11, SD = 0.85) versus “no” (M = 3.61, SD =0.77)  for whether they engage in 
medication monitoring in their agreement that medication monitoring is a role in which 
school psychologists should be involved,  t (137) = -3.48,  p < .001.  Levene’s test was 
not significant, therefore equal variances are assumed. 
 Overall, there is a relatively weak relationship between school psychologists’ 
beliefs regarding medication monitoring and their actual reported practice.  However, 
when comparing group means between school psychologists who reported engaging in 
medication monitoring versus those who did not, a statistically significant difference was 
found.   
Table 7 
Independent Samples t-test Examining Beliefs Regarding Medication Monitoring and 
Reported Involvement in Medication Monitoring (n = 137) 
 
 
Medication Monitoring Involvement 
Yes 
 
M 
(SD) 
No 
 
M 
(SD) 
 
 
t 
 
 
df 
 
 
Sig 
(2-
tailed) 
Agreement with Medication Monitoring  4.11 
0.85 
3.61 
    0.77 
-3.48 137 .001 
 
Note. The scale of the variable “Medication monitoring involvement” was assessed by respondents 
indicating either “Yes” or “No”. The scale of the variable “Medication monitoring beliefs” was assessed 
using the following: 1=Strongly Disagree, 2=Disagree, 3=Neither Agree nor Disagree, 4=Agree, 
5=Strongly Agree.    
*p < .05.   
Research Question 3: What are the current medication monitoring practices of 
school psychologists? (a) What types of data are collected when engaged in 
medication monitoring? (b)What is the frequency (e.g., daily, weekly, or monthly) 
that medication monitoring data are collected? (c) What is the frequency (e.g, daily, 
weekly, or monthly) that medication monitoring data are shared? (d) With whom is 
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medication monitoring information shared (e.g., primary care provider, parents, 
school-based intervention team, teachers)?   
Question 3a: What types of data are collected when engaged in medication 
monitoring?  
 Responses from item 20 were examined to address this research question. This 
item asked respondents to indicate which procedures they used to monitor medications as 
well as how often each procedure was used. The categories included behavior rating 
scales, direct behavior observations, child and teacher interviews, work samples, 
curriculum based assessments, and grades. A response category of “Other” was included 
with item 20 so respondents could list types of data collected that were not included on 
the survey.  Respondents who listed a category under “Other” (n = 18) did not report a 
frequency with which they utilized the particular method.  As a result, N/A is reported.  
Table 8 presents the percentages of respondents who reported using each method of data 
collection.  Of note, the categories in Table 8 are not mutually exclusive.   Respondents 
were able to report the use of more than one method in the practice of medication 
monitoring.  Overall, respondents reported utilizing a multitude of methods in medication 
monitoring rather than relying on a single method.  Methods endorsed by 50% or more of 
the respondents included direct behavior observations, teacher rating forms, child 
interviews, and teacher interviews.   
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Question 3b: What is the frequency (e.g., daily, weekly, or monthly) that medication 
monitoring data are collected?   
Data from survey question 20 were used to analyze the results for this question 
(see Table 8).  The majority of respondents reported utilizing each method one time per 
month or less overall but did report using a variety of methods (e.g., teacher interviews, 
child interviews, review of work samples). Some (21%) of respondents reported utilizing 
teacher interviews every other week (e.g., bi-weekly) while approximately 15% reported 
using direct behavior observations on a bi-weekly basis and 14% on a weekly basis.  A 
very small percentage (less than 2%) reported using direct behavior observations and 
curriculum-based assessment procedures on a daily basis.   Some respondents utilized the 
“Other” category reporting a variety of medication monitoring methods used to collect 
data.  Specifically, consultations with the school nurse, daily behavior reports from 
teachers, response to counseling sessions, and statewide data from standardized tests 
were reported.  Overall the number of respondents using the “Other” category was lower 
than those who utilized the provided categories (i.e., < 20).   
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Table 8  
Frequency of Medication Monitoring Practices (n = 77) 
 
Medication Monitoring 
Method 
 
n 
 
Percentage 
 
<1 time 
month 
 
1x 
month 
 
Approx 1x  
every 2 
weeks 
 
1x 
week 
 
Daily 
 
 
N/A or 0 
times 
Teacher rating forms  71 50.7%  54..9% 22.5% 12.7% 1.4% 0% 8.5% 
Direct behavior 
observations 
74 52.9% 24.3% 44.6% 14.9% 13.5% 1.4% 1.4% 
Parent rating forms 69 49.3% 62.3% 17.4% 8.7% 1.4% 0% 10.1% 
Parent interviews   
69 
49.3% 52.2% 30.4% 7.2% 1.4% 0% 8.7% 
Child self-report rating 
scales 
  
69 
49.3% 53.6% 14.5% 4.3% 4.3% 0% 23.2% 
Child interview 70 50% 42.9% 25.7% 11.4% 8.6% 0% 11.4% 
Teacher interview 73 52.1% 20.5% 45.2% 20.5% 9.6% 0% 4.1% 
Permanent products  66 47.1% 31.8% 25.8% 10.6% 6.1% 0% 25.8% 
Curriculum based 
assessment 
66 47.1% 33.3% 16.7% 10.6% 6.1% 1.5% 31.8% 
Grades 69 49.3% 50.7% 26.1% 10.1% 1.4% 0% 11.6% 
Other         
        Consultation with 
school  
        nurse 
4 3.0% N/A N/A N/A N/A N/A N/A 
        Discipline records 3 2.0% N/A N/A N/A N/A N/A N/A 
        Statewide reading  
        assessment 
2 1.4% N/A N/A N/A N/A N/A N/A 
        Response to counseling  1 .07% N/A N/A N/A N/A N/A N/A 
        Daily behavior reports  
        from teacher 
8 6.0% N/A N/A N/A N/A N/A N/A 
                
Note. The scale for the variables with the exception of the category “Other” was assessed using the 
following: 1=Strongly Disagree, 2=Disagree, 3=Neither Agree nor Disagree, 4=Agree, 5=Strongly Agree.  
The scale for the category “Other” was free response and the n along with the percentage of respondents 
who endorsed each are presented.  
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Question 3c: What is the frequency (e.g., daily, weekly, or monthly) that medication 
monitoring data are shared?   
 To address this research question, responses from item 19 which asked “when you 
engage in medication monitoring, in general with whom and how often do you share the 
information?” were examined.  The categories included (“< 1 time per month”, “1 time 
per month”, “Approximately 1 time every two weeks (i.e., bi-weekly)”, 1 time a week”, 
“Daily”, and “N/A or zero times”.  Table 9 presents the frequencies displayed as 
percentages that respondents reported in sharing medication monitoring information as 
well as with what entity it was shared.  The majority of school psychologists reported 
sharing medication monitoring information with parents, teachers, prescribing physicians, 
and the school-based intervention team typically one time per month or less.  However, 
some school psychologists reported sharing of information on a more frequent basis.  
Specifically, when sharing information with parents, nine percent of school psychologists 
reported sharing information bi-weekly and seven percent reported sharing information 
weekly.  When sharing information with teachers, 15 percent reported sharing 
information weekly as well as bi-weekly, and three percent reported daily sharing of 
information.  When sharing information with the prescribing physician, one percent 
reported bi-weekly sharing of information and no respondents reported weekly or daily 
sharing information. When sharing information with the school-based intervention team, 
18 percent reported sharing information bi-weekly, five percent weekly, and one percent 
daily.  Respondents who utilized the “Other” category did not list the frequency in which 
they share information, only the entity with which they share the information.  The next 
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section will discuss which entities respondents report sharing information with in more 
detail. 
Question 3d: With whom are medication monitoring data shared?  
 In order to address this research question responses from item 19 were examined.  
The potential categories included Parents, Teachers, Prescribing Physicians, School-
based intervention teams, and a category for “Other”.  Table 9 presents the results.  
Overall, respondents indicated sharing information with Parents, Teachers, Prescribing 
Physicians, and the School-based intervention team relatively equally (range is 52.1%-
54.2%).  Regarding responses to the “Other” category, 9% of respondents indicated they 
share medication monitoring information with a child’s therapist, 3% reported sharing 
information with the school nurse and one respondent (0.02%) indicated they shared 
information with an outside agency.   
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Table 9  
Frequency of Sharing Medication Monitoring Information and with Whom it is Shared (n 
= 77) 
 
Sharing of Information 
 
n 
 
Percentage 
 
<1 time 
month 
 
1x 
month 
 
Approx 1x  
every 2 
weeks 
 
1x 
week 
 
Daily 
 
 
N/A or 0 
times 
Parents  76 54.2% 40.8% 40.8% 9.2% 6.6% 0% 2.6% 
Teacher 75 53.5% 30.7% 37.3% 14.7% 14.7% 2.7% 0% 
Prescribing Physician  73 52.1% 39.7% 12.3% 1.4% 0 % 0% 46.6% 
School-based Intervention 
Team 
74 52.8% 25.7% 41.9% 17.6% 5.4% 1.4% 8.1% 
Other         
          Outside care agency 3 0.02% N/A N/A N/A N/A N/A N/A 
Mental 
health/therapists 
13 9% N/A N/A N/A N/A N/A N/A 
          Nurse (school) 4 3% N/A N/A N/A N/A N/A N/A 
 
Research Question 4: What types of training (pre-service vs. in-service) do school 
psychologists receive in the practice of medication monitoring?   
 To address this research question, responses from survey item 12 were examined 
which asked “Have you received training at any time in the past on monitoring the effects 
of psychotropic medications in students?”  Respondents had the option of answering 
either “yes” or “no” to this question.  If respondents indicated “yes”, they were then 
directed to indicate what types of medication monitoring training they have received from 
a list of potential types of trainings.  Overall, 63.3% (n = 88) of respondents reported 
receiving some training related to medication in the past.   The results are presented in 
Table 10.   
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Table 10  
 
Percentage of Respondents with Training in Medication Monitoring (n = 140) 
 
Medication Monitoring Training 
 
n Percent. 95% Confidence Interval 
Yes 88 63.3% 57.18-69.42% 
No 51 36.7% 26.14-47.26% 
 
 Table 11 illustrates the descriptive statistics regarding the types of medication 
monitoring training (e.g., in-service, reading of scholarly journals, and graduate courses 
containing a component on medication monitoring) respondents reported receiving at any 
point in the past. The majority of respondents reported receiving a variety of types of 
training.  The amount of training reported by respondents varied considerably.  
Specifically, the means and standard deviations for each training category from highest to 
lowest are as follows: Personal reading of scholarly journal articles in hours (M =17.43, 
SD = 22.74),  Personal reading of textbooks in hours (M = 14.32, SD = 17.25), In-service 
training (M = 3.73, SD = 4.08),  attending professional conferences (M =3.41, SD = 3.63), 
online training (M = 1.93, SD = 3.03), and graduate courses containing a component on 
the topic of medication monitoring (M = 1.65,  SD = 2.03).  Overall, respondents reported 
the greatest amount of training in personal reading of scholarly articles and textbooks. 
However, the scale for those two variables was in hours while the other types of training 
were measured in number of trainings or graduate courses.  Therefore, comparisons must 
be made carefully.        
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Table 11 
 
Descriptive Statistics of Types of Medication Monitoring Training (n =77) 
 
 n M  
 
SD Sk Ku Range 
 In-service training  75 3.73  
 
4.08 2.41 6.42 0-20 
Online training 
 
59 1.93 3.03 1.59 1.56 0-12 
Professional 
conferences 
71 3.41 3.63 2.90 10.93 0-20 
Graduate courses  66 1.65 2.03 2.08 3.41 0-8 
Personal reading of 
scholarly journals 
(hours) 
72 17.43 22.74 2.40 5.85 0-100 
Personal reading of 
textbooks (hours) 
71 14.32 17.25 2.40 7.92 0-100 
Other  
         Consultation    
         with physicians  
 
4 N/A N/A N/A N/A N/A 
 
Note. The scale for each of the variables is as follows: In-service training, online training, professional 
conferences, graduate coursework, personal reading of scholarly journals and textbooks, and “other” were 
continuous variables measured by the number of trainings, conferences, courses, and hours spent reading 
reported.  
 
Research Question 5: What are the perceived barriers and facilitators to medication 
monitoring?  
 Responses from item 21 (barriers) and item 22 (facilitators) were used to answer 
this research question.  Item 21 required respondents to answer the following question:  
“To what extent do you agree or disagree that each of the following factors is a barrier to 
school psychologists monitoring psychotropic medications students are taking?”  
Respondents were provided with a list of 11 factors, including one that allowed them to 
 76 
 
write in an “Other” option, and were asked to indicate the extent to which they agreed or 
disagreed to the factor on a 5-point Likert scale ranging from “Strongly Agree” to 
“Strongly Disagree”. The means and standard deviations represent respondents as a group 
reporting their opinion on the degree to which they agreed or disagreed that each factor is 
a barrier.  “Strongly Disagree” would be represented as a 1 while “Strongly Agree” is at 
the highest end of the scale at 5.  The results of respondents’ ratings are presented in 
Table 12.   Three factors were rated by respondents as the largest barriers to medication 
monitoring compared to the remaining eight.  Lack of time was reported to be the largest 
barrier (M = 3.60, SD = 1.13, n = 137).  Lack of community support was listed as second 
(M = 3.42, SD = 1.07, n = 137), and insufficient knowledge regarding how to monitor 
medications was third (M = 3.10, SD = 1.19, n = 137).    The remaining eight factors were 
rated fairly evenly on whether they were viewed as a barrier.  Specifically, means for 
each were below 3.0 indicating respondents were neutral regarding whether these factors 
served as barriers to medication monitoring.   
 Some respondents listed their own barriers to medication monitoring under the 
category for “Other”.  Although the number of respondents using the “Other” category is 
low (n = 37), responses included perceptions that  primary care pediatricians prescribe the 
greatest amount of psychotropic medications and have little training in monitoring, 
situations where the student’s behavior improves and the need to actively monitor 
decreases, and an overall unawareness of the school psychologist’s skill set related to 
medication monitoring.   
 Survey item 22 utilized an open ended response format for respondents to list 
factors they felt were facilitators to medication monitoring.  A post-hoc thematic analysis 
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based on recommendations from Lofland and Lofland (1995) was completed regarding 
respondents’ reports of facilitators to medication monitoring.  Specifically, each response 
was carefully examined by the researcher and categories were developed.  A total of 10 
categories were created based on respondents’ reported perceptions of facilitators.  These 
categories sufficiently represent the perceptions of respondents with respect to facilitators 
to medication monitoring based on recommendations from Lofland et al. (1995).  Not all 
respondents listed facilitators.  Specifically, out of the total sample of 140 completed 
surveys, 109 included information related to facilitators. This represents approximately 
78% of respondents who answered the question related to facilitators to medication 
monitoring.  These results are presented in Table 13.  
 Regarding facilitators, respondents most frequently reported ongoing professional 
training (26%) as an important facilitator to medication monitoring. This category could 
include in-service training, professional conferences, online training, and supervision 
from colleagues.  The second most frequently listed facilitator was communication and 
collaboration with the prescribing physician (21%). This category included the degree to 
which the school psychologist and prescribing physician were able to communicate 
effectively. The third most frequently listed category was including medication 
monitoring activities on a student’s Individualized Education Plan (IEP).  Specifically, 
16.5% of respondents reported inclusion of specific tasks related to medication 
monitoring as a facilitator.  However, none of the respondents indicated whether this is a 
practice that is currently occurring in their schools, or simply a recommendation that 
including medication monitoring on a student’s IEP would facilitate the process of 
collecting this type of data.  Other facilitators listed were less frequently cited by 
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respondents (< 6.5%) but did cover a fairly broad range of facilitators such as having 
access to existing tools to make medication monitoring easier, less students on caseload, 
and increased role flexibility.  
Table 12  
Perceptions of Barriers to Medication Monitoring (n = 140) 
 
Factor 
 
n 
 
M 
SD 
 
Sk 
Ku 
 
Strongly 
Disagree 
 
Disagree 
 
Neither 
Agree 
nor Disagree 
 
Agree 
 
Strongly 
Agree 
 
Lack of time 137 3.60 
1.14 
-.67 
-.43 
5.1% 16.2% 13.2% 44.1% 21.3% 
Insufficient knowledge 137 3.10 
1.19 
-.25 
-1.09 
10.3% 26.5% 14.7% 39.7% 8.8% 
Lack of resources 136 2.74 
1.02 
0.08 
-1.09 
9.6% 38.2% 22.1% 28.7% 1.5% 
Lack of teacher support  137 2.23 
.902 
0.69 
0.39 
19.1% 50% 21.3% 8.1% 1.5% 
Lack of support of other 
colleagues 
 137 2.31 
.920 
0.62 
0.09 
16.8% 48.9% 22.6% 10.2% 1.5% 
Lack of parent support 137 2.65 
1.02 
0.21 
-.66 
12.4% 35.8% 29.2% 19.7% 2.9% 
Lack of administrative 
support 
137 2.58 
.998 
0.21 
-.75 
13.1% 38.7% 27% 19.7% 1.5% 
Lack of support from 
school psychologists’ 
supervisor 
137 2.41 
1.07 
0.56 
-.25 
20.4% 38.7% 24.8% 11.7% 4.4% 
Teacher availability 137 2.91 
1.07 
0.08 
-.888 
8% 32.8% 25.5% 27.7% 5.8% 
Lack of community 
support 
137 3.42 
1.07 
-.39 
-.71 
3.6% 20.4% 20.4% 41.6% 13.9% 
Other         
Pediatricians prescribe 5 4% N/A N/A N/A N/A N/A N/A 
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most psychotropic 
medications, little training 
in monitoring 
Student’s behavior 
improves, active 
monitoring decreases 
11 8% N/A N/A N/A N/A N/A N/A 
Belief monitoring is 
completed informally with 
no school psychologist 
input 
2 1.5% N/A N/A N/A N/A N/A N/A 
Unawareness of school 
psychologist skill set  
13 9.42% N/A N/A N/A N/A N/A N/A 
School is unaware of 
student taking medication 
6 4.34% N/A N/A N/A N/A N/A N/A 
 
Note. The scale for the variables with the exception of the category “Other” was assessed using the 
following: 1=Strongly Disagree, 2=Disagree, 3=Neither Agree nor Disagree, 4=Agree, 5=Strongly Agree.  
The scale for the category “Other” was free response and the n along with the percentage of respondents 
who endorsed each are presented.  
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Table 13   
Perceptions of Facilitators to Medication Monitoring (n = 109) 
Facilitator n Percent 
Ongoing professional training  29 26.6% 
 
Communication between school psychologist and 
prescribing physician 
23 21.1% 
 
Collaboration between, school psychologist, teacher 
and parents 
16 6.0% 
 
Graduate training 1 0.9% 
 
More role flexibility       2 0.8% 
Less students on caseload 7 6.4% 
Easy to use method to monitor (e.g., checklists) 7 4.6% 
Including on IEPs as progress monitoring 
requirement 
18 16.5% 
Time 5 4.6% 
Increased community support for medication 
monitoring  
1 0.9% 
 
Note. The scale for the variables related to facilitators of medication monitoring was assessed using an 
open-ended question “Given the listing of potential barriers in the previous question, please list what you 
feel may be a facilitator to school psychologists monitoring psychotropic medications”.  The items were 
coded into 10 categories and the n along with percentage of respondents endorsing a facilitator in each 
category are presented.  
 
Research Question 6: What is the direction and strength of the relationship between 
geographic location, degree level, training program philosophy, type of school 
served, types of training related to medication monitoring, and the frequency of 
medication monitoring by school psychologists?    
 Responses from survey items 10 (geographic location), 5 (degree level), 13 
(training program philosophy), 11 (type of school served), and 12 (types of training 
related to medication monitoring) in relation to item 16 (frequency of medication 
monitoring) were examined in order to answer this research question.   Spearman rank 
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order correlation coefficients were calculated for all variables related to this research 
question.  The Spearman method was chosen due to the nature of the variables of interest 
which included ordinal data.  Prior to conducting Spearman rank order correlation 
coefficients, preliminary analyses were performed to ensure there were no violations of 
the assumptions of normality, linearity, and homoscedascticity.  Specifically, a scatter 
plot was generated to examine the data for outliers that fell outside of expected ranges 
(i.e., exceeding three standard deviations) based on recommendations from Talbachnick 
and Fidell (2007).  The results are presented in Table 14.  Overall, small to moderate 
significant positive correlations were observed for respondents who reported practicing in 
a rural school setting (rs = 0.39) and for those who received in-service training (rs = 0.38) 
while a moderate negative correlation was observed for the variable non-student 
allocation (rs = -.43).  Other correlations for geographic location, types of school served, 
and types of training were small to moderate but did not demonstrate a statistically 
significant relationship with frequency of medication monitoring.  In summary, the 
results of the analyses indicate small to moderate relationships between some 
demographic and training variables.  However, the majority of intercorrelations were not 
significant when using Cohen’s (1988) guidelines.
 82 
 
Table 14  
 
Intercorrelations between Demographic Variables and Medication Monitoring Practices  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Correlation is significant at the p = 0.05 level (2-tailed). 
Note. The scale for each of the variables is as follows: School setting was measured by geographic location 
delineated as 1= urban, 2= suburban, 3= rural.   Degree level: 1= Master’s, 2 = Masters +30, 3= Specialist, 
4= Doctorate. Program philosophy was measured on a 5-point Likert scale delineated as 1= primarily 
assessment focused, 2=somewhat assessment focused, 3= balanced between assessment and intervention 
focus, 4= somewhat intervention focused, 5= primarily intervention focused. Grade level was measured in 
percentages of time spent in each setting reported including a category for non-student allocation in which 
no direct student contact occurs.  In-service training, online training, professional conferences, and graduate 
coursework were continuous variables measured by the number of trainings, conferences, and courses  
reported.  Medication monitoring frequency was measured on a scale of 1=annually, 2=quarterly, 3=once 
per month, 4= once per week, 5= daily, 6=two to five times per day, 7= five or more times per day. The 
sample sizes range from a minimum of 59 cases to a maximum of 140
Variable Frequency of Medication Monitoring 
Spearman’s Rho 
n 
Sig. (2-tailed) 
Geographic location   
          Urban  -.94 77 
0.42 
          Suburban 0.12 77 
0.29 
          Rural  0.39 77 
0.03* 
Type of school (grade level)   
          Pre-K 0.14 77 
0.46 
          K-5 -.265 77 
0.16 
          6-8 -.04 77 
0.83 
          9-12 0.21 77 
0.27 
          Non-student allocation -.43 77 
0.02* 
In-service training 0.38 58 
0.04* 
Online training -.001 45 
0.99 
Professional conferences 0.34 53 
0.07 
Graduate courses 0.06 48 
0.77 
Personal Reading Scholarly  
Articles 
0.27 56 
0.16 
Personal Reading Textbooks 0.25 56 
0.19 
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Additional Information 
 This section examines two further areas of interest in addition to the original 
research questions.  Predictive analyses examined how well degree level, training 
program philosophy, geographic location, types of training reported related to medication 
monitoring predict the frequency of medication monitoring by school psychologists.  
Additionally,   the types of disorders school psychologists reported monitoring 
medications for were examined.   
How well does degree level, training program philosophy, geographic location, types 
of training reported related to medication monitoring predict the frequency of 
medication monitoring by school psychologists?   
 To determine which variables were most predictive of the frequency of 
medication monitoring by school psychologists, a simultaneous multiple regression 
analysis was utilized.  Specifically, respondents’ answers to items 5 (highest degree 
earned), 10 (geographic location), 12 (types of training reported), 13 (philosophy of 
training program), and 16 (frequency of medication monitoring) were examined.  Some 
survey items from each aforementioned variable were not included in the model if less 
than 50 respondents completed the items (e.g., number of professional conferences and 
online trainings attended). Respondents’ answers to item 10 were re-coded into dummy 
variables due to their categorical nature in order to be entered into the regression model.  
Prior to conducting the multiple regression analysis, preliminary analyses were conducted 
to ascertain whether any violations of the assumptions of normality, linearity, 
multicollinearity, and homoscedascticity occurred.  First, the data were examined for the 
presence of multicollinearity.  When variables are highly correlated in a multiple 
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regression analysis it becomes difficult to identify the unique contribution of each 
variable in predicting the dependent variable (i.e., frequency of medication monitoring) 
because the variables which are highly correlated are predicting the same variance in the 
dependent variable.  The values examined to determine if multicollinearity exists in the 
model were tolerance and variance inflation factor (VIF).  Tolerance is an indicator how 
much variability of an independent variable is not explained by the other variables.  
Tabachnick and Fidell (2007) recommend using a value of less than .10 as a guideline.  
Specifically, if a value is very small (<.10) this indicates the multiple correlations with 
other variables is very high.  The VIF is interpreted as the inverse of tolerance and 
Tabachnick et al. (2007) recommend values above 10 are a cause for concern.  Two 
independent variables exceeded these guidelines (personal reading of scholarly texts and 
personal reading of textbooks and other sources).  Due to the sensitivity of regression 
analyses to violations of the assumption of multicollinearity, these variables were 
combined in the model due to the very similar nature of each variable (i.e., personal 
reading of scholarly journals and textbooks).  Next, the data were examined for violations 
of the assumptions related to normality, linearity, and homoscedascticity.  Utilizing the 
probability plots generated by SPSS and the regression standardized residual plot the data 
were examined for violations to the aforementioned assumptions.  The data fell in a linear 
pattern suggesting no major deviations from normality.  Additionally, the scatterplot 
generated by SPSS was examined.  Specifically, the standardized residuals were visually 
examined and appeared to follow a rectangular pattern that did not deviate past 3.3 or -
3.3 standard deviations from the mean.  This pattern is desired as it suggests no violations 
of the assumptions needed to utilize a multiple regression analysis (Tabachnick et al., 
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2007).  The Mahalanobis distance was also examined to check for outliers.  The critical 
chi-square value based on the degrees of freedom was calculated to be 24.32 using an 
alpha level of .001.  Additionally, the value for Cook’s Distance was examined to 
determine the degree to which the data identified as an outlier were having an undue 
influence on the overall model.  Tabachnick et al. (2007) recommend values that exceed 
1 are potentially exhibiting undue influence on the overall regression model and should 
be removed from the dataset.  As a result, three data points fell significantly outside of 
this value and were subsequently removed from the dataset.  The results of the analysis 
are presented in Table 15.  An alpha level of .05 was used to determine statistical 
significance.  The regression analysis, predicting frequency of medication monitoring 
from seven predictor variables, was not statistically significant, F (6, 44) = 0.86, p = .98, 
R² = .11   
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Table 15 
Simultaneous Regression Analysis for Demographic Variables and Training Predicting 
Medication Monitoring Practices (n = 51) 
Variable  B SE B β t p 
Constant 2.11 0.66  3.17 0.03 
Degree level 0.08 0.20 0.06 0.39 0.69 
Program philosophy 0.22 0.15 0.25 1.49 0.14 
School setting       
            Urban Rural = reference -.01 0.41 -.01 -0.01 0.99 
            Suburban Rural = reference -.10 0.36 -.05 -.27 .78 
In-service training 0.02 0.04 0.09 0.60 0.55 
Personal Reading 0.02 0.04 0.07 0.46 0.64 
R2 0.11 
0.86 F 
p  <  .05 
Note: For the School Setting variable, Rural is denoted as the reference category.  The scale for each of the 
variables is as follows: Degree level: 1= Master’s, 2 = Masters +30, 3= Specialist, 4= Doctorate.  Program 
philosophy was measured on a 5-point Likert scale delineated as 1= primarily assessment focused, 
2=somewhat assessment focused, 3= balanced between assessment and intervention focus, 4= somewhat 
intervention focused, 5= primarily intervention focused.  School setting was measured by geographic 
location delineated as 1= urban, 2= suburban, 3= rural.  In-service training, and personal reading, were 
continuous variables measured by the number of trainings, conferences, hours spent reading, and courses 
reported.  
 
For what types of disorders do school psychologists monitor medications?   
 Participant responses from survey item 18 asking “In the last year, approximately 
how many students have you monitored the effects of psychotropic medications for each 
of the following disorders?” were examined.  The response categories included Attention-
Deficit/Hyperactivity Disorder, Oppositional Defiant Disorder, Depressive Disorders, 
Anxiety Disorders, Autism Spectrum Disorders, Asperger’s Disorder, Bipolar  Disorder, 
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Tourettes Syndrome and/or Tic Disorders, Thought Disorders (e.g., schizophrenia), 
Multiple Disorders (e.g., intellectual disability and disruptive behavior disorder), and a 
category for “Other Disorders” in which respondents were asked to write in the name of 
the disorder.  Respondents were asked to indicate the number of students for whom 
medication monitoring data were collected in the last year using a scale of: “0”, “1-2”, 
“3-5”, “6-8”, and “9+”.  The results are presented in Table 16.  Overall, the majority of 
respondents reported monitoring medications for a variety of disorders.  It is important to 
note the results in the table below are not mutually exclusive.  Specifically, respondents 
were able to report monitoring medications for a variety of disorders.  The disorder with 
the highest reported incidence of medication monitoring was Attention-
Deficit/Hyperactivity Disorder (M =1.80, SD = 0.96, n = 75) while the lowest was 
Thought Disorders (M = 0.27, SD = 0.660, n = 44).  When examining the specific 
percentages in Table 14 for each disorder which school psychologists reported 
monitoring medications, most reported doing so for less than six students in the past 
school year.  Additionally, a small number of school psychologists utilized the category 
“Other Disorders” and reported monitoring medications for seizure disorders and 
Obsessive Compulsive Disorder.  However, they did not indicate what frequency or the 
number of students for whom they monitored medications.   
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Table 16  
Disorders for which School Psychologists Report Monitoring Medication in the Past 
Year (n =77) 
 
Disorder 
 
n 
 
M 
SD 
 
Sk 
Ku 
 
0 
 
1-2 
 
3-5 
 
6-8 
 
9+ 
 
Attention-Deficit/Hyperactivity 
Disorder (ADHD) 
75 1.80 
0.96 
0.98 
0.35 
1.3%  44.0% 37.3% 8% 9.3% 
Oppositional Defiant Disorder, 
Conduct Disorder or other 
externalizing disorder 
50 1.26 
1.22 
0.86 
-.074 
32% 34% 18% 8% 8% 
Depressive Disorders 46   0.93 
1.06 
 
1.06 
0.46 
43.5% 32.6% 13% 8.7% 2.2% 
Anxiety Disorders 48 0.81 
0.82 
1.09 
1.29 
37.5% 50% 6.3% 6.3% 0% 
Autism Spectrum Disorders 55 0.93 
1.10 
1.35 
1.45 
43.6% 34.5% 12.7% 3.6% 5.5% 
Asperger’s Disorder 46 0.67 
1.01 
1.92 
3.77 
56.5% 30.4% 6.5% 2.2% 4.3% 
Bipolar Disorder 51 0.80 
1.01 
1.54 
2.77 
41.2% 47.1% 3.9% 5.9% 2.0% 
Tourettes Syndrome and/or Tic 
Disorders 
42 0.31 
.563 
1.68 
2.02 
73.8% 21.4% 4.8% 0% 0% 
Thought Disorders 44 0.27 
.660 
2.69 
7.31 
81.8% 11.4% 4.5% 2.3% 0% 
Multiple Disorders 43 0.53 
1.07 
2.12 
3.85 
74.4% 9.3% 9.3% 2.3% 4.7% 
Other Disorders         
      Seizure Disorders  2 1.5% N/A N/A N/A N/A N/A N/A 
      Obsessive Compulsive     
      Disorder 
4 3% N/A N/A N/A N/A N/A N/A 
Note. The scale for the variables with the exception of the category “Other” was assessed using the 
following: 0= no students, 1-2=one-two students, 3-5=three to five students, 6-8=six to eight students, 
9+=nine or more students.  The scale for the category “Other” was free response and the N along with the 
percentage of respondents who endorsed each are presented.  
 
 
 
 
Number of Students 
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Summary of Results 
 In summary, the results of this study found the majority of school psychologists 
believe medication monitoring is an appropriate role (74.3%); however, intercorrelations 
between school psychologists’ beliefs regarding medication monitoring and the 
frequency of actual reported practice was low (rs = 0.24).  School psychologists who 
reported they engaged in medication monitoring in any amount held more favorable 
views of this practice being an important role for school psychologists than those who did 
not report engaging in medication monitoring at all.  School psychologists reported using 
a variety of methods to monitor medications (e.g., behavior rating scales, teacher 
interviews, direct behavior observations) and utilized each method on average once per 
month.  However, some respondents (< 2%) did report engaging in medication 
monitoring as frequently as once per day.  With respect to receiving training related to 
medication monitoring when broadly defined, over half the sample reported receiving 
training at some time in the past (63.3%).  The types of training included in-service 
trainings, graduate coursework, and personal reading of scholarly articles.  School 
psychologists reported a number of barriers as well as facilitators to engaging in 
medication monitoring.  The most frequently reported barriers were lack of time and 
community support (e.g., lack of interest from physicians) as well as insufficient 
knowledge to engage in medication monitoring.  The facilitators most frequently reported 
were availability of ongoing professional training, communication and collaboration 
between the school psychologist and prescribing physician, and inclusion of medication 
monitoring activities on a student’s IEP.  
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 When examining the direction and strength of the relationship between various 
demographic variables (e.g., degree level) and engagement in medication monitoring, 
weak correlations were observed.  This was also found when examining the relationship 
between types of training reported in medication monitoring and frequency of engaging 
in the practice.  School psychologists did report engaging in medication monitoring for a 
variety of disorders.  The most frequent disorder was Attention Deficit/Hyperactivity 
Disorder while the least frequent was Thought Disorders.   When examining how well 
demographic variables and types of training related to medication monitoring and 
actually predict engagement in the practice, the results were not significant.  Specifically, 
the percentage of variance in medication monitoring accounted for by the demographic 
and training variables was not significantly different than zero.  
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Chapter Five 
Discussion 
Summary of the Study  
The purpose of this study was to provide a comprehensive examination of the 
current practices of school psychologists related to medication monitoring for the most 
commonly prescribed psychotropic medications used with children and adolescents.  
Specifically, this study examined the beliefs and practices of school psychologists related 
to medication monitoring, such as the types and frequency of data collected, with whom 
data are shared, and the types of training received related to medication monitoring.   
Finally, this study examined the perceived facilitators and barriers to medication 
monitoring in public schools by school psychologists.   
This chapter will summarize the study results and discuss these findings with 
respect to the extant literature.  In addition, this chapter will discuss the implications of 
the results for school psychologists, identify limitations of the study, and provide 
directions for future research.  
 Research questions 1 and 2: Beliefs related to medication monitoring and 
frequency of self-reported medication monitoring practices.   
 The purpose of these research questions was to determine the beliefs school 
psychologists hold related to medication monitoring as part of their overall professional 
activities as well as the relationship between those beliefs and actual medication 
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monitoring practices.  Findings from this study indicate the majority of respondents 
(74.3%) “Agree” or “Strongly Agree” (M = 3.93, SD = 0.85) that medication monitoring 
is an appropriate role for school psychologists.   
 The following definition for medication monitoring was used in the survey: 
“Medication monitoring is defined as including the following activities (not an 
exhaustive list); consultation with classroom teacher(s) and paraprofessionals, utilization 
of behavior rating scales, behavior observations, review of work samples or curriculum-
based assessments”. These findings are similar to extant research on this topic.  
Specifically, Guereasko-Moore, DuPaul, and Power (2005) found the majority of 
respondents to their survey also reported being in agreement that medication monitoring 
is a practice in which school psychologists should be engaged.  These findings indicate 
that over time, the beliefs regarding medication monitoring among school psychologists 
have remained relatively stable.  However, it is important to note the samples were drawn 
from different populations.  Specifically, Guereasko-Moore et al. (2005) drew from a 
national sample of 700 school psychologists who were members of the National 
Association of School Psychologists (NASP) while the current study was based upon a 
sample of 273 school psychologists who were members of the Florida Association of 
School Psychologists (FASP).  
 School psychologists who reported “Agree” or “Strongly Agree” indicating their 
endorsement of medication monitoring as a role in which they should be engaged 
reported differing levels of practice.  Specifically, school psychologists were asked to rate 
the frequency in which they engage in medication monitoring for the previous school 
year.  However, when examining group differences among school psychologists who 
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reported “yes” to the question asking if they have monitored medications at all over the 
past school year and their beliefs regarding medication monitoring, statistically 
significant results were obtained. Specifically, school psychologists who reported they do 
engage in medication monitoring also reported perceiving this to be a needed role more 
than those who did not report engaging (i.e., answered “no”) in medication monitoring.   
Overall, the strength of the relationship between school psychologists’ beliefs regarding 
medication monitoring and their actual reported practice was relatively weak.  However, 
school psychologists who reported engaging in medication monitoring also reported more 
favorable beliefs regarding the practice than those who did not.    
Several plausible hypotheses can be generated from these results.  Specifically, 
many school psychologists may agree that medication monitoring is an appropriate 
professional role; however, they may not have time to engage in this practice. Extant 
research found numerous barriers exist that prevent school psychologists from engaging 
in roles outside traditional activities such as psychoeducational testing and assessment for 
special education services (DuPaul & Carlson, 2005; Sulkowski, Jordan, & Nguyen, 
2009).   Additionally, school psychologists may agree medication monitoring is an 
activity in which they should be engaged, but not have suitable training or tools to carry 
out the practice.   In the current study, school psychologists were asked to report barriers 
to medication monitoring as well as facilitators.  Many school psychologists reported lack 
of time, insufficient training, and community support as reasons for not engaging in 
medication monitoring.  Previous research also reported similar findings.  Specifically, 
Carlson, Demaray, and Hunter-Oehmke (2006) conducted a survey examining multiple 
facets of school psychologist’s practices related to medication monitoring.  Not having 
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sufficient training to engage in medication monitoring was found to be a significant 
barrier as was having high caseloads which likely would result in insufficient time to 
conduct these practices.  The barriers and facilitators to medication monitoring will be 
discussed in further detail later in this chapter.  
Research Question 3: Current Medication Monitoring Practices of School 
Psychologists.  
This research question examined four facets of medication monitoring.  
Specifically, it examined (a) the types of data collected when engaged in medication 
monitoring, (b) the frequency of data collection, (c) the frequency with which data are 
shared, and (d) with whom medication monitoring data are shared.   
 Findings indicate school psychologists utilize various types of data when engaged 
in medication monitoring.  Teacher rating forms, direct behavior observations, and 
interviews were the preferred methods of medication monitoring data collection.  In the 
current study, respondents reported selecting methods of data collection that are sensitive 
to small changes in performance over time compared to less sensitive measures (e.g., 
grades and annual state-wide standardized tests).  Methods that allow for ongoing 
progress monitoring such as behavior rating scales used in conjunction with direct 
behavior observations were likely preferred due to their objectivity when used as a multi-
modal method of data collection.  This speaks to the unique training school psychologists 
possess which enables them to be well suited for the practice of medication monitoring.  
Other researchers have advocated for school psychologists to engage in medication 
monitoring to a greater extent due to their unique training (DuPaul & Carlson, 2005).  
Specifically, these authors purport that many school psychologists are well-suited to 
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assist in medication monitoring considering the following skills in their repertoire: (a) 
training in data-based decision making; (b) training in systematic problem-solving 
examining factors from an ecological perspective; (c) ability to progress monitor using 
methods sensitive to small changes in performance; and (d) the ability to observe children 
and adolescents in the school environment which typically is significantly different from 
office-based settings or other community settings.  Furthermore, previous research has 
found the behaviors children and adolescents exhibit in non-school settings may be 
dramatically different from the levels of behaviors exhibited in the classroom (Pelham et 
al., 2000).  Methods school psychologists used to collaborate will be discussed in further 
detail later in this chapter.  
Along with possessing unique training, school psychologists have at their disposal 
a number of structured and standardized tools to use that are efficacious in the practice of 
medication monitoring.  For example, the use of structured direct behavior observation 
tools such as the Behavior Observation System for Students (BOSS; Shapiro, 2010) 
provides concrete data to evaluate academic engagement and off-task behaviors that may 
be impacted by various dosage levels of psychotropic medications.  In fact, research 
supports the use of the BOSS for evaluating the effects of medications on students with 
Attention-Deficit/Hyperactivity Disorder (ADHD).  Specifically, Power, DuPaul, 
Shapiro, and Kazak (2003) found this tool was efficacious in helping to determine the 
impact of stimulant medications being used to treat the symptoms of ADHD.    
In the current study, approximately half of the entire sample reported using some 
method of data collection to engage in medication monitoring. This indicates school 
psychologists are engaging in medication monitoring; however, the frequency in which 
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they are monitoring the effects of medications is limited.  Specifically, less than 1% of 
respondents reported collecting medication monitoring data on a daily basis.  It may not 
be possible for many school psychologists to collect data daily given time and resource 
constraints.  Although it is recommended that during titration of a stimulant medication 
careful monitoring occur to achieve the best dose-response relationship (DuPaul & 
Carlson, 2005), this may not be feasible for most practicing school psychologists.   It 
should be noted that this study did not differentiate between whether the school 
psychologist or a delegate collected these data. Specifically, a paraprofessional, school 
counselor, or classroom teacher may have collected data related to a student’s response to 
medication and potentially shared it with the school psychologist. Additionally, this study 
found a higher than average school psychologist to student ratio.  This study found 38.9% 
of the sample reported a school psychologist to student ratio of 1: >3,000.  When 
comparing this ratio to the most recent data from the National Association of School 
Psychologists membership survey, only 4% of school psychologists nationally reported 
having a ratio of 1: > 3,000 (Curtis et al., 2010).  As a result, due to their overall 
caseloads it is possible school psychologists in the current study may have other members 
of the school assist in collecting data related to medication monitoring.  Future research 
should explore this aspect of medication monitoring more in-depth.     
The majority (i.e., 68%) of school psychologists reported using each of the 
potential medication monitoring methods once per month or less.  It is plausible that 
school psychologists collect data regarding a child’s response to medication at regularly 
scheduled times that occur once per month such as before a school-based intervention 
team meeting.   School psychologists reported direct behavior observations, child 
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interviews, and teacher interviews as the most frequent methods to be used once per 
week. Previous research found similar data collection methods to be viewed by school 
psychologists as the most effective and feasible in the school setting (Guerasko-Moore, et 
al., 2005). However, this study was limited to utilizing these data collection methods for 
students with ADHD. The current study examined the use of the aforementioned data 
collection methods for a wide variety of disorders.  Future research should explore how 
school psychologists integrate multiple sources of information when sharing data with 
others (e.g., school-based intervention team, teacher, or prescribing physician).    
The results varied with what entities school psychologists are sharing medication 
monitoring information and the frequency with which they are engaging in this practice.  
Specifically, the majority (66%) of school psychologists who reported collected these 
data indicated that they share the data with others one time per month or less.  
Approximately 15% of school psychologists reported sharing medication monitoring 
information weekly with teachers.  Also, 17.6% of school psychologists reported sharing 
medication monitoring information bi-weekly at school-based intervention team 
meetings. Lastly, a small percentage of school psychologists reported daily sharing of 
information with the teacher (2.7%) and school based-intervention team (1.4%).  With 
respect to the prescribing physician, school psychologists, on average, reported sharing 
information approximately one time per month or less (52%).  This is consistent with 
previous research.  Specifically, Carlson, Demaray, and Hunter-Oehmke (2006) found in 
a study examining school psychologists’ caseloads in which students were receiving 
medications that 62% of school psychologists reported working with physicians to 
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evaluate medication trials for children but the collaborative monitoring was infrequent 
(e.g., < 1 time per month).   
When examining the frequency in which medication monitoring information is 
shared, it is hypothesized that medication monitoring data are shared with teachers and 
other staff at regularly scheduled meetings in which a discussion of the identified child is 
already taking place. Sharing of information with prescribing physicians occurs less 
frequently due to barriers in communication and collaboration.  Extant research has found 
physicians are unsure with whom to communicate or how to forge alliances with the 
educators including school psychologists (Bradley-Klug et al., 2010).  Additionally, 
Bradley-Klug et al. (2010) found physicians reported first attempting to collaborate with 
the school nurse and classroom teacher, rather than the school psychologist.  Future 
research should examine more specific methods school psychologists and physicians 
would find effective and feasible to communicate on a more frequent basis.   
Research Question 4: Types of Training School Psychologists Receive in the Practice 
of Medication Monitoring. 
 Sixty-three percent of respondents reported receiving training related to 
medication in the past.  In-service training, professional conferences, and personal 
reading of scholarly articles were reported to be the most frequent avenues through which 
school psychologists received this training.  In comparison, Carlson and colleagues 
(2006) examined school psychologists’ practices related to medication monitoring and 
found the majority of school psychologists have not had formal university training in 
child psychopharmacology (81%).  The primary method school psychologists acquired 
background knowledge in child psychopharmacology was through professional 
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workshops (88%) and independent reading (96%). In contrast to the Carlson et al. study, 
45% of respondents in the current study indicated they had some type of training related 
to medication monitoring as a component of a graduate course.  Carlson et al. (2006) 
examined this aspect of training and found only 19% of respondents reported graduate 
coursework containing a component that includes topics related to medication 
monitoring.   As will be discussed later in this chapter, the elapsed time between studies, 
increased attention towards psychotropic medications being taken by children, and 
evolving school psychology training programs may contribute to the differences in 
findings.   
With respect to personal reading of scholarly articles as well as other sources of 
information (e.g., textbooks), a wide range was reported from 0-100 hours of time spent 
reading on the topic.  A number of hypotheses are offered to explain these findings.  
School psychologists are required to participate in a variety of trainings and in-service 
presentations each year in most districts.  Additionally, school psychologists who hold a 
Nationally Certified School Psychologist (NCSP) credential are required to obtain 
National Association of School Psychologists (NASP) approved continuing education 
units (CEUs) every three years.  It is possible that school psychologists who hold the 
NCSP seek training in medication monitoring through the resources offered by NASP.  
Future research examining this hypothesis would need to draw upon a stratified national 
sample.   
 This study found a higher percentage of school psychologists reporting training in 
medication monitoring than previous research.  Specifically, Guerasko-Moore et al. 
(2005) found 41.9% of school psychologists reported receiving training in medication 
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monitoring compared to 63.3% in the current study.  It is hypothesized because this 
current study was conducted six years after the original study, the number of training 
opportunities available to school psychologists regarding the importance of medication 
monitoring have increased.  Factors such as polypharmacy (Bush, 2006) and the overall 
increase in the number of school age students prescribed medication (Lam, & Collier-
Crespin, 2003; Aman, Lam, & Van Bourgondien, 2005; Witwer & Lecavalier, 2006) may 
also contribute to increased training opportunities for school-based personnel.    
Another important hypothesis is related to where each sample was drawn.  The 
study by Guerasko-Moore et al. (2005) was based on a national sample of 700 school 
psychologists who were members of NASP.  The current study included a sample of 375 
members of FASP. The demographics of each sample are inherently different.  It is 
possible that the training opportunities offered in Florida are different than what may be 
available elsewhere in the nation.   
 Overall, respondents report receiving training in medication monitoring and report 
a variety of sources to obtain this training.  Future research could examine the 
opportunities available at professional conferences that offer training on medication 
monitoring in the schools.  Additionally, future research could examine the types of 
training that prepare school psychologists to most competently engage in medication 
monitoring.  Examining the modalities and preferences for training on this topic could be 
yet another research avenue in the future.   
Research Question 5: Perceived Facilitators and Barriers to Medication Monitoring  
 Respondents reported a number of factors that facilitate the practice of medication 
monitoring.  Professional training on medication monitoring was most frequently 
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reported by respondents as a facilitator to increasing the probability that a school 
psychologist would engage in this practice.  Also, collaboration among school 
psychologists and other professionals (e.g., prescribing physician, teachers, and parents) 
was cited as an important facilitator.  Extant research on collaboration among school 
psychologists and other professionals supports this as an important facilitator for other 
activities such as collaborating among school psychologists and other professionals to 
create a wrap-around support system of care for students receiving services from multiple 
entities (Carlson, 2008; Drotar, Palmero & Berry, 2004).  In fact, creating more cohesive 
systems of care is advocated as the first step in effective medication monitoring (Wodrich 
et al., 1999).    Additionally, enhancing communication and collaboration between 
school-based personnel and medical entities can improve overall wrap-around services 
for children and adolescents.  For example, research has found problems related to 
adherence with medication regimens occurs due to a myriad of factors such as intolerable 
side effects and misunderstanding of the need to regularly take medication (Bussing, 
Koro-Ljungberg, & Gary, 2005; Gau, Chen, & Chow, 2008).   Because many 
medications are taken to improve symptoms of disorders that may impact both academic 
and social functioning, school personnel can also be part of the overall team that helps 
educate children and families about the importance of adhering to medication regimens as 
part of an overall home-school partnership.   
A number of respondents suggested integrating medication monitoring as a 
practice on students’ Individualized Education Plans (IEP) as a method to facilitate the 
practice of medication monitoring.  This would also likely enhance a cohesive system of 
care for children and adolescents.  Time needs to be set aside for the school psychologist 
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to collect data and communicate with outside parties.  Obtaining easy to use checklists or 
other data collection methods were also listed as an important facilitator to medication 
monitoring.  There are a number of tools available that would be useful in the practice of 
medication monitoring.  For example, the BOSS (Shapiro, 2011) is sensitive to small 
changes in behavior that would directly bear a relationship to students who are being 
titrated for a medication or who may be experiencing negative side effects (e.g., 
drowsiness)  impacting academic functioning.  Additionally, as previously mentioned, 
tools such as the BOSS have been shown to be effective in helping to determine the right 
dosage for stimulant medications for a particular child (Power et al., 2003).  This is 
important as the same dosage of a medication can have dramatically different effects on 
different children (Christensen, Helms, & Chesney, 1999).  Having more time via fewer 
students on school psychologists’ caseloads was also reported to facilitate medication 
monitoring.  The current study found 38.9% of school psychologists reported a school 
psychologist to student ratio at or exceeding 1:3,000.  NASP recommends a school 
psychologist to student ratio of no more than 1: 2,500 (Curtis et al., 2010).  Thus, 
respondents to this survey have higher school psychologist to student ratios than is 
recommended by NASP.  
 This study found differences compared to previous research with respect to 
facilitators for medication monitoring.  Specifically, Guerasko-Moore et al. (2005) found 
teacher support to be the strongest facilitator for medication monitoring.  This particular 
facilitator was not reported by respondents in the current study. One hypothesis is that the 
current study employed an open-ended question format regarding facilitators in contrast 
to the forced-choice question on the survey related to barriers.  It is possible school 
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psychologists did not consider teacher support as a facilitator to medication monitoring 
due to the way the question was structured.  It is hypothesized that respondents may have 
not fully understood this question or may have not completely answered it due to its 
location on the survey as the last question.   
This study found no predictive relationship between a number of variables (i.e., 
degree level, geographic location, types of training, and training program philosophy) and 
whether a school psychologist engages in medication monitoring.  It is likely a number of 
other factors not examined in this study are related to whether a school psychologist 
engages in this practice.  The predictive nature of various variables and their effects on 
school psychologist’s medication monitoring practices will be discussed later in this 
chapter.   
 With respect to barriers to medication monitoring, respondents reported a number 
of factors that inhibit their efforts to engage in this practice.   Lack of time was reported 
as the largest barrier.  This finding is consistent with previous research.  Specifically, 
Guerasko-Moore et al. (2005) found time was the largest barrier to medication 
monitoring.  Lack of community support (e.g., physicians and other providers) was listed 
as the second largest barrier in the current study.  Insufficient knowledge about 
medication monitoring or methods to engage in the practice was listed as the third largest 
barrier.  Interestingly, a number of respondents utilized the “Other” category to write in 
their own barriers.  Responses included concerns that pediatricians prescribe the most 
amount of psychotropic medications yet have the least amount of training compared to 
other medical professionals was listed as a barrier.  Extant research has found that the 
vast majority of psychotropic medications are indeed prescribed by primary care 
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physicians rather than specialists (i.e., child and adolescent psychiatrists), particularly in 
rural areas (Bush, 2006).  It is likely that pediatricians are unaware of the skills a school 
psychologist may possess or how to collaborate with them for activities including 
medication monitoring.  Bradley-Klug and colleagues (2010) examined pediatricians’ 
perceptions of school psychologists’ roles.  Pediatricians reported being largely unaware 
of school psychologists’ training, indicated misperceptions about their role within public 
schools, and being unsure of with whom to communicate at the school regarding a child 
in their care.  Future research should examine how to minimize barriers school 
psychologists listed such as time and insufficient training along with the most effective 
methods school psychologists could use to forge relationships with not only primary care 
pediatricians but other professionals such as therapists and child/adolescent psychiatrists.  
Examining methods to increase a cohesive system of care related to ongoing professional 
communication and collaboration among school psychologists and other professionals 
would be another important research avenue.  
Research Question 6: Direction and Strength of the Relationship Between 
Geographic Location, Degree Level, Training Program Philosophy, Type of School 
Served, Types of Training Related to Medication Monitoring, and Frequency of 
Medication Monitoring by School Psychologists. 
 This research question examined the interrcorrelations between the school 
psychologists’ geographic location, degree level, training program philosophy, type of 
schools served, types of training related to medication monitoring, and the frequency 
school psychologists engage in medication monitoring.  Overall, small to moderate 
significant positive correlations were found for some variables.  Specifically, school 
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psychologists who reported practicing in a rural school setting (rs = 0.39) and who 
received in-service training (rs = 0.38) were the only significant positive correlations.  A 
significant moderate negative correlation was found for school psychologists who 
reported spending some of their time in a non-student allocation (rs = -.43).    
 Several hypotheses could explain the lack of significant relationships between the 
variables examined other than those previously mentioned.  First, the variables selected 
were chosen based on an a priori decision of which variables may potentially be related 
to school psychologists’ practice of medication monitoring.  It is possible other variables 
not examined in this study may be more closely related such as school psychologist to 
student ratio, years practicing as a school psychologist, and specific facilitators that 
enable a school psychologist to engage in medication monitoring.  Second, this study 
utilized an overall sample size of 240 respondents.  However, for this particular research 
question, only 77 were included in the analyses as only data from respondents who 
indicated they do engage in medication monitoring practices were included in the 
analyses.  Therefore, the relatively small sample size may have impacted the results.  A 
larger nationally representative sample may produce different findings than the current 
study.  An additional possible reason could be that the variables examined truly are not 
related to the degree to which a school psychologist monitors medications.  That is, 
students are taking medications at all grade levels and geographic locations across the 
U.S. based on previous prevalence research (Abrams, Flood, & Phelps, 2006; Zito, 2003).  
Also, although it was hypothesized that school psychologists trained at the doctoral level 
would have more specialized coursework containing components related to medication 
monitoring, it is possible this is not the case. Training programs may integrate topics 
 106 
 
related to medication monitoring throughout coursework, regardless of degree level.  It 
was also hypothesized that training programs which are more intervention focused than 
assessment focused would incorporate components related to medication monitoring at 
greater rates.  It is possible this is also not occurring in practice.  Overall, the relatively 
weak relationships found should be examined more closely in future research as a larger 
sample size and examining different interrelationships between variables could yield 
more significant results.  
Additional Information: Predictors of Medication Monitoring 
 Significant results were not obtained predicting medication monitoring practices 
by a variety of demographic, training, graduate program philosophy, and degree level 
variables.  Some specific survey items needed to be removed from the regression model 
due to having a low n. Additionally, some variables had to be combined (e.g., types of 
training) in the analyses due to violations of the assumptions for a multiple regression 
analysis.  The overall sample size for this question was 51, and several respondents’ data 
had to be eliminated due to falling outside of acceptable ranges for a multiple regression 
analysis (i.e., Mahalanobis distance exceeding cutoff).  Therefore, on one hand it is 
plausible the independent variables examined (i.e., degree level, training program 
philosophy, type of school served, and types of training reported) were not predictive of 
whether a school psychologist engages in medication monitoring.  As was found when 
examining the intercorrelations between demographic, training program philosophy, type 
of schools served, and degree level, there simply may not be a strong relationship 
between these variables as well as there not being a single variable that predicts whether 
a school psychologist is going to engage in medication monitoring.  Alternatively, it is 
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possible due to limitations with this study’s sample size that significant results could not 
be obtained.  Future research should examine what factors are truly predictive of school 
psychologists’ engagement in medication monitoring at a number of levels.  First, 
replicating this study would further answer whether there are factors that predict if a 
school psychologist engages in medication monitoring.  Second, examining the multitude 
of other facets that could be predictive (e.g., assignment to a center school specializing in 
educating children with behavior disorders) of a school psychologist engaging in 
medication monitoring could also further determine if there are other factors predicting 
school psychologists’ engagement in medication monitoring.  Lastly, examining the 
relationship between the school psychologist to student ratio as part of an overall multiple 
regression analysis that includes other demographic variables may glean new interesting 
information and significant results.   
Additional Information: Types of Disorders for which School Psychologists Monitor 
Medications    
 The current study sought to build on previous research examining medication 
monitoring practices of school psychologists for stimulant medications utilized to treat 
the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD; Guerasko-Moore et 
al., 2005).  One facet of the current study was to examine other disorders of youth for 
which school psychologists may be monitoring medications.  Respondents were asked on 
the following scale how many students per disorder they have monitored in the past 
school year:  (0 = no students), (1-2 = one-two students), (3-5 = three to five students), 
(6-8 = six to eight students), and (9+ = nine or more students).  The scale for the category 
“Other” was free response in case there were disorders for which school psychologists 
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were involved in medication monitoring that were not listed. The disorders which were 
listed included Attention-Deficit/Hyperactivity Disorder, Oppositional Defiant Disorder, 
Depressive Disorders, Anxiety Disorders, Autism Spectrum Disorders, Asperger’s 
Disorder, Bipolar Disorder, Tourette’s Syndrome and/or Tic Disorders, Thought 
Disorders (e.g., schizophrenia), Multiple Disorders (e.g., intellectual disability and 
disruptive behavior disorder), and a category for “Other Disorders” in which respondents 
were asked to write in the name of the disorder.   
The results of this study indicate school psychologists are monitoring medications 
for a variety of disorders.  Although it is not surprising that ADHD was reported as the 
most frequent disorder in which medication monitoring occurred, other disorders were 
also prevalent albeit at lower rates.  The disorders for which school psychologists 
reported monitoring medications are listed from most to least frequent: ADHD, 
Oppositional Defiant/Conduct Disorder, Autism Spectrum Disorders, Depressive 
Disorders, Anxiety Disorders, Bipolar Disorder, Multiple Disorders, Asperger’s Disorder, 
Tourette’s Syndrome and/or Tic Disorders, and Thought Disorders.  The results indicate 
school psychologists are monitoring medications for a variety of disorders but on average 
for 1-2 students per year.   
Overall, the results of this research question provide interesting new data.  As 
previously noted, this study sought to expand on previous research which examined 
medication monitoring practices of school psychologists limited to students with ADHD.  
This study found a multitude of disorders for which school psychologists are monitoring 
medications.  Previous research found 39% of children and adolescents receiving special 
education services were prescribed a psychotropic medication to inhibit externalizing 
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behaviors and 17% of those students were administered multiple medications (Mattison, 
1999).   
 These findings build upon previous research in determining what other disorders 
of youth school psychologists may be monitoring medications.  To date, no extant 
research has examined this topic.  Future research could look at a myriad of other factors 
that facilitate or inhibit school psychologists from monitoring medications for various 
disorders.  Additionally, it would be interesting to know what types of methods school 
psychologists use for each type of disorder.  Potentially interviewing school 
psychologists about how they monitor medications for specific disorders (e.g., 
externalizing vs. internalizing) along with what tools they feel are most effective and 
feasible for each particular disorder would likely yield interesting new information.    
Implications for Practice: Facilitating Medication Monitoring Practices  
 Findings from this study build on previous research and underscore the need for 
school psychologists to engage in medication monitoring in certain situations.  
Significant numbers of children are attending school while being prescribed a number of 
psychotropic medications aimed at treating symptoms that frequently inhibit school 
performance.  For example, Mattison (1999) found over one third of students receiving 
special education services in public schools are prescribed a psychotropic medication and 
a quarter of those are prescribed multiple medications to treat externalizing behavior 
problems.  Many of the medications being prescribed to children and adolescents have 
not had substantial research conducted on their effects in children (Bush, 2006).   
Furthermore, the practice of off-label prescribing along with the fact that children are 
being prescribed medications by multiple professionals further demonstrates a need to 
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monitor.  Specifically, given the findings that many children are prescribed various 
psychotropic medications for the purposes of treating symptoms that primarily occur in 
the school setting (DuPaul & Carlson, 2005), medication monitoring is a necessary role 
for school psychologists.   
The results of this study indicate most school psychologists are in agreement and 
feel medication monitoring is a necessary role.  However, a number of barriers exist as 
found in the current study.  Specifically, time was reported as a major barrier.   
Advocating for allocated time to conduct activities related to medication monitoring, 
writing into IEPs the need to conduct monitoring of the child’s response to medication, 
and communication with the prescribing physician will alleviate some of the barriers 
reported in this study.  Additionally, as most practitioners in the field of school 
psychology hold a specialist degree or equivalent, integrating coursework into both the 
doctoral and specialist level training programs may increase future practitioner’s 
awareness of methods to engage in medication monitoring.  Many programs train 
practitioners to use methods such as direct behavior observation augmented with tools 
such as the BOSS (Shapiro, 2010) as well as utilizing a collaborative consultation model 
with school personnel.  These skills practitioners possess make them well suited to 
engage in medication monitoring when provided with the knowledge of how and time to 
do so. 
Given the extant research on barriers to communication and collaboration with 
physicians as well as school psychologists (Bradley-Klug et al., 2010), it is important to 
continue to address and reduce barriers to creating a bi-directional system of care for 
children who may be prescribed multiple psychotropic medications and are experiencing 
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adverse side effects.  Helping parents to learn to trust school personnel and fostering a 
partnership to benefit the child along with permission for the school psychologist and 
prescribing physician to engage in communication will help alleviate some of the barriers 
to medication monitoring.   
Finally, as children increasingly are prescribed multiple medications and the 
demands in the classroom increase, teachers may not notice subtle changes in children 
that could be the result of a negative side effect to a medication.  School psychologists 
with the knowledge and skills to assess small changes in behavior or academic 
performance may be able to educate teachers on strategies to identify problems a child is 
experiencing related to medication side effects.  Using a systematic problem-solving 
approach, school psychologists can assist teachers and other educators to hypothesize 
causes for poor academic performance that may be related to psychotropic medication.     
Limitations 
 This study has several limitations that should be considered when interpreting the 
results.  A total of 140 usable surveys were included in the analyses to answer each 
research question with a notable exception.  Respondents who indicated they had not 
engaged in medication monitoring over the past school year were directed to skip a 
number of questions.  Not all participants reported engaging in medication monitoring.  
As a result, some research questions were analyzed with a smaller total sample (i.e., 77 
respondents).  This may have affected the significance of some of those analyses, 
particularly the predictive analyses.   
 Although this study resulted in a relatively high response rate of 61%, 
generalization of the results is restricted by the use of a convenience sample.  The sample 
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was drawn from the FASP membership database representing only school psychologists 
practicing in the State of Florida.  It also is irrespective of whether the school 
psychologists are also members of NASP or hold a NCSP credential.  As a result, there 
are specific threats to ecological validity which affects the degree to which a researcher 
can generalize findings across settings or to other situations (Johnson & Christensen, 
2004).   Another potential threat to the results of this study is population validity.  This 
refers to the degree to which a researcher can generalize the findings to other groups 
(Johnson & Christensen, 2004).   As previously mentioned, this study employed a 
convenience sample of school psychologists practicing in the State of Florida.  The 
results of this study cannot be generalized outside of the population used in the study and 
also must be cautiously compared to previous research as other studies on this topic 
referenced in this chapter utilized a different study population.   
 There is a possibility that responses obtained do not accurately reflect the 
practices of school psychologists engaged in medication monitoring.  The construct of 
social desirability bias may affect the results (Dillman, Smyth, & Christian, 2009).  
Specifically, respondents may assume the researcher wants them to engage in medication 
monitoring practices and may overestimate their practices as a result.  Additionally, this 
study utilized an up-front incentive format in which each participant was given a dollar 
bill enclosed in the survey as an incentive for participation.  Respondents may have felt 
indebted to the researcher due to receiving a tangible reward upfront and mistakenly 
reported engaging in medication monitoring when in fact they do not. Consistent with 
social exchange theory, the cost to the respondent was kept to a minimum by utilizing a 
brief (e.g., 15-20 minute completion time) survey and providing a self-addressed stamped 
 113 
 
envelope in which to return it based on recommendations from Dillman et al. (2009).   In 
order to minimize the probability of this occurrence, the survey methodology utilized an 
anonymous design along with pilot testing the survey with 26 school psychologists which 
produced clear and concise operational definitions of medication monitoring as well as 
clearly worded questions.   
Future Directions  
 This study was the first to examine the medication monitoring practices of school 
psychologists for a wide variety of psychotropic medications prescribed to youth.  The 
findings of this study inform both the literature and practice at the pre-service and in-
service levels.  However, because this study was the first to address these topics, it should 
be replicated with a larger more representative sample of school psychologists.  There are 
a number of possible future directions to be considered based upon the outcomes of this 
study.  .  Examining specific types of training at the pre-service and in-service levels 
could help inform what types of training are most useful to school psychologists who 
wish to engage in medication monitoring.  Developing standard protocols for use in 
school districts to assist teachers, paraprofessionals, and school psychologists with 
medication monitoring would likely help increase this practice.  Assessing other school 
personnel such as administrators’ beliefs regarding medication monitoring would be 
another likely avenue for future research.  Further examining pediatricians, child and 
adolescent psychiatrists, neurologists, and other non-physician providers’ beliefs 
regarding medication monitoring would also be helpful.  Determining new methods to 
collaborate and communicate as well as what types of information (e.g., concise reports) 
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are most beneficial to both the school psychologist and prescribing physician will be 
informative.  
Final Thoughts  
 Although it is largely believed that medication monitoring is an important role for 
school psychologists, more research on how to effectively monitor a child’s response to 
medication is needed.  More than half of the school psychologists in this study reported 
engaging in some form of medication monitoring.  A number of barriers were reported 
that currently limit the ability to collect data and inhibit the frequency of data collection 
and monitoring.  Respondents offered feedback regarding facilitators that would enhance 
the ability of the school psychologist to engage in medication monitoring.  Future 
research is necessary to further explore this topic and to assist in the development of 
strategies to promote medication monitoring as a role for school psychologists.   
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Appendix A 
Cover Letter to Participants 
 
School Psychologists’ Practices of Psychotropic Medication Monitoring  
 
Dear FASP Member, 
   
You have been selected as a current FASP member to participate in a research study 
examining the role of school psychologists in medication monitoring of students. The goals 
of this study are to determine the types of psychotropic medications (e.g., Adderall, 
Clonidine, Risperidone) school psychologists monitor, how the effects of medications are 
evaluated, with whom monitoring data are shared (e.g., teachers, parents, physicians), and 
the barriers to and facilitators of medication monitoring in our schools.  Findings will 
inform both pre-service and in-service training on this important topic.   
 
You are being asked to be part of this study because you are a practicing school 
psychologist whose primary employment is in a school setting. If you do not currently 
work in a school setting, please check the box on the front of the survey and return it in the 
postage paid envelope.  We would like you to be a participant in this study, regardless 
of the amount of time you currently spend monitoring psychotropic medications.  The 
survey will only take 10-15 minutes to complete and we have provided you with a 
postage-paid envelope to use in returning the survey. Participation is completely 
voluntary and involves completing the enclosed questionnaire and returning it in the 
enclosed envelope within 2 weeks.  Your participation will be anonymous.  A completed 
and returned survey will be considered consent to participate in the study.  Should we 
publish or disseminate findings from this study, only aggregate data will be published.  As 
a token of our appreciation for participating in this study, a dollar bill is enclosed to 
use for coffee, snack, or anything you wish.   
 
This study was approved by the University of South Florida Institutional Review Board 
(IRB # Pro00002616) and the Florida Association of School Psychologists. “The Florida 
Association of School Psychologists encourages school psychologists to participate in 
the completion of surveys which increase the knowledge base about the practice of 
school psychologists in the state of Florida.  This survey has been approved by the 
Research Committee and FASP Executive Board”.  
 
Thank you in advance for your time and assistance with this research study.  If you have 
any questions or concerns about the study, please feel free to contact us at the numbers or 
emails listed below.  We also invite you to contact us if you would like to obtain the 
results of the study as soon as they are available.  If you have questions about your 
rights as a participant in this study, general questions, or have complaints, concerns or 
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issues you want to discuss with someone outside the research, call the USF IRB at (813) 
974-5638.  
 
Thank you so much for your participation.   
 
Sincerely, 
 
Jason Hangauer, Ed.S, NCSP                    Kathy Bradley-Klug, Ph.D, NCSP 
Principal Investigator-Doctoral Candidate       Chairperson of  Dissertation Research-
Associate Professor 
School Psychology Program         School Psychology Program 
University of South Florida                                     University of South Florida 
jhangaue@health.usf.edu                                         kbradley@usf.edu      
(813) 974-0605           (813) 974-9486  
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Appendix B 
Follow-up Letter to Participants 
 
School Psychologists’ Practices of Psychotropic Medication Monitoring 
 
Dear FASP Member, 
 
You have been selected as a current FASP member to participate in a research study 
examining the role of school psychologists in medication monitoring of students. The goals 
of this study are to determine the types of psychotropic medications (e.g., Adderall, 
Clonidine, Risperidone) school psychologists monitor, how the effects of medications are 
evaluated, with whom monitoring data are shared (e.g., teachers, parents, physicians), and 
the barriers to and facilitators of medication monitoring in our schools.  Findings will 
inform both pre-service and in-service training on this important topic.   
 
Our records indicate that as of this date, we have not received a completed 
questionnaire from you.  Please take a few minutes to complete and return the enclosed 
survey in the postage paid envelope.  The survey will only take 10-15 minutes to 
complete.  We would like you to be a participant in this study, regardless of the amount of 
time you currently spend monitoring psychotropic medications.  If you do not work in a 
school setting at all, please check the box on the front of the survey and return it in 
the postage paid envelope.  
Your participation will be anonymous.  A completed and returned survey will be 
considered consent to participate in the study.  Should we publish or disseminate findings 
from this study, only aggregate data will be published.  As a token of our appreciation 
for participating in this study, a dollar bill was enclosed in the first copy of the survey 
you received to use for coffee, snack, or anything you wish.   
 
This study was approved by the University of South Florida Institutional Review Board 
(IRB # Pro00002616) and the Florida Association of School Psychologists. “The Florida 
Association of School Psychologists encourages school psychologists to participate in 
the completion of surveys which increase the knowledge base about the practice of 
school psychologists in the state of Florida.  This survey has been approved by the 
Research Committee and FASP Executive Board”.  
 
Thank you in advance for your time and assistance with this research study.  If you have 
any questions or concerns about the study, please feel free to contact us at the numbers or 
emails listed below.  We also invite you to contact us if you would like to obtain the 
results of the study as soon as they are available.  If you have questions about your 
rights as a participant in this study, general questions, or have complaints, concerns or 
issues you want to discuss with someone outside the research, call the USF IRB at (813) 
974-5638.  
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Thank you so much for your participation.   
 
Sincerely, 
 
Jason Hangauer, Ed.S, NCSP                    Kathy Bradley-Klug, Ph.D, NCSP 
Principal Investigator-Doctoral Candidate       Chairperson of  Dissertation Research-
Associate Professor 
School Psychology Program         School Psychology Program 
University of South Florida                                     University of South Florida 
jhangaue@health.usf.edu                                         kbradley@usf.edu      
(813) 974-0605           (813) 974-9486  
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Appendix C 
Survey 
 
 
 
If you work in a school part- or full-time, please continue.  If you DO NOT work in a school 
setting at all, please DISCONTINUE at this point, check the box below, and return the survey in 
the enclosed return envelope.  
  I do not currently work in a school. 
 
 
 
 
 
 
1. Gender  (Circle one)    A. Female    B. Male    
 
2. Ethnicity  (Circle one)           
A. Black/African American C. Native American/Alaskan Native       E. Hispanic American/Latino 
B. Asian American/Pacific Islander  D. White/Caucasian F. Other _____________ 
 
3. State in which you are currently employed (e.g., FL, NY, CA) _____________ 
 
4. Job Status (circle one)      A. Full-time employee    B. Part-time employee  C. 
Contractual/independent consultant 
 
5. Highest degree earned in School Psychology (circle one)                                                           
A. Bachelor’s   B. Master’s    C. Master’s +30   D. Specialist E. Doctorate 
 
6. Highest graduate degree earned NOT in school psychology:  please specify degree (e.g., None, 
Doctorate)____________  
and the area in which degree was earned (e.g., Educational Leadership) ____________________ 
 
7. Years practicing as a school psychologist (post-degree, including present year)   _____________ 
 
8. The approximate number of students you serve (school psychologist: student ratio) 
____________ 
 
9. Number of buildings that you currently serve _____________________  
 
10. Primary location of current work site (please choose one):  
          School Psychologists’ Practices of Psychotropic Medication Monitoring  
 
SECTION 1: BACKGROUND INFORMATION 
Please respond to all items based on your school practice for the 2010-2011 school year.  
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Urban ________Suburban________ Rural ________ 
 
11.  Currently, what percentage of your time is spent working with students in these grade categories? 
Please make sure your percentages total 100%. 
Pre-K: _________    K-5: _________6-8: ________9-12: ___________ Non-student 
allocation________ 
 
 
 
 
 
 
 
12. Have you received any type of training at any time in the past on monitoring students taking 
psychotropic medications?  
 
Definition of Medication Monitoring:  
Medication monitoring is defined as including the following activities (not an 
exhaustive list): Consultation with classroom teacher(s) and paraprofessionals, 
utilization of behavior rating scales, behavior observations, review of work 
samples, or curriculum-based assessment. If there are activities not listed that 
you engage in which you believe are considered medication monitoring, please 
make a note of it in the space below, it will be very helpful information on this 
important topic.  
Additional medication monitoring 
activities:__________________________________________________________________________ 
              If  Yes, please circle the type(s) of 
training received. If      
   No, please move onto question #13 
 
 
A. In-Service Trainings  
      (with some component    
      devoted to medication  
      monitoring) 
 
Number of trainings =______    
 
N/A (I have not attended 
in-service trainings on 
this topic) 
B.  Online Trainings  
Number of trainings =______    
 
N/A (I have not attended 
online trainings on this 
topic) 
 
C. Professional Conferences 
 
 
Number of professional 
conferences =______  
 
 
N/A (I have not attended 
professional conferences  
on this topic) 
Yes  No 
SECTION 2: Medication Monitoring Training  
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D. Graduate courses with a  
     component focused on  
     psychotropic medications 
 
 
Number of courses  = ______   
 
N/A (I have not taken 
courses with a component 
focused on this topic) 
E. Personal reading of scholarly  
     journals focused on   
    monitoring psychotropic  
    medications 
 
Number of hours spent reading 
= ______  
 
N/A (I have not read 
scholarly articles focused 
on this topic) 
F. Personal reading (e.g.,  
    textbooks, other sources on  
    monitoring psychotropic  
    medications)  
 
Number of hours spent reading 
= ______  
 
N/A (I have not read 
textbooks or other sources 
focused on this topic) 
G. Other (Please describe) Number of hours spent = 
________   
Describe 
activity____________________
__________________________ 
 
N/A (I have not spent 
other time  on this topic 
not already included) 
 
13. What was the overall philosophy of your school psychology training program (e.g., courses, 
practicum, internship)? 
       (Circle one): 
Primarily  
Assessment 
Focused 
Somewhat 
Assessment 
Focused 
Balanced Between 
Assessment and 
Intervention Focused 
Somewhat 
Intervention 
Focused 
Primarily 
Intervention 
Focused 
1 2 3 4 5 
 
 
14. Please indicate your opinion of this statement:  
       
Monitoring the effects of psychotropic medications for students with emotional and behavior disorders 
(e.g.,ADHD, depression, anxiety) and other disorders is a role in which school psychologists should be 
involved. 
  
Strongly 
Disagree Disagree 
Neither Agree nor 
Disagree Agree Strongly Agree 
1 2 3 4 5 
 
15. Have you been involved in monitoring the effects (beneficial or negative) of a psychotropic 
medication in any manner for a student with whom you work? (See definition of medication 
monitoring broadly defined at question #12) 
 
      
 
 
If Yes, move to question #16, If No, please move to question #21.  
 
16.  How frequently do you monitor the effects (beneficial or negative) of a psychotropic medication 
for students with whom    
       you work? (Circle one): 
Annually Quarterly (i.e., fall, winter, spring) 
Once per 
month 
Once per 
week Daily 
 
2-5 Times 
per day 
 
5+ Times 
per day 
Yes  No 
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1 2 3 4 5 6 7 
 
17.  In the past year, how many students have you monitored for the effects (beneficial or negative) of    
        a psychotropic medication in any manner? (Circle one): 
 
 
18.  In the last year, approximately how many students have you monitored for the effects of 
       psychotropic medications for each of the following disorders (if known)? 
                               Disorder  Number of students for whom medication 
monitoring data were collected in the past 
year  
A. Attention-Deficit/Hyperactivity Disorder 
(ADHD)     0 1-2         3-5  6-8 9+   N/A 
B. Oppositional Defiant Disorder, Conduct 
Disorder or 
     any other externalizing disorder 
    0 1-2         3-5  6-8 9+ N/A 
C. Depressive Disorders     0 1-2         3-5  6-8 9+ N/A 
D. Anxiety Disorders     0 1-2         3-5  6-8 9+ N/A 
E. Autism Spectrum Disorders      0 1-2         3-5  6-8 9+ N/A 
F. Aspergers Disorder     0 1-2         3-5  6-8 9+ N/A 
G. Bipolar Disorder     0 1-2         3-5  6-8 9+ N/A 
H.Tourettes Disorder and/or Tic Disorders      0 1-2         3-5  6-8 9+ N/A 
I. Thought Disorders (e.g., schizophrenia)     0 1-2         3-5  6-8 9+ N/A 
J. Multiple Disorders (e.g., mental retardation and 
disruptive behavior 
    Disorders) 
    0 1-2         3-5  6-8 9+ N/A 
K. Other Disorders (please write in below) 
    0 1-2         3-5  6-8 9+ N/A 
 
19. When you do engage in medication monitoring, in general with whom and how often do you share   
the information?  
                               
 
         Sharing of information  
   Less    
than 1x      
month 
 
1x month  
 About 
Once 
Every 
  2 Weeks 
 
   1x a     
   week 
        
Daily 
N/A 
Or 0 times 
A. Parents 1 2 3 4 5 N/A 
           0 1-2         3-5         6-8       9-11      12-14          15+ 
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B. Teacher 1 2 3 4 5 N/A 
C. Prescribing Physician 1 2 3 4 5 N/A 
D. School-based intervention team 
(multiple individuals) 1 2 3 4 5 N/A 
 
 
E. Other (please specify below)  
______________________________ 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
N/A 
 
 
20. Please indicate how often you have used the following procedures to monitor the effects of 
psychotropic medications on students: 
 
                                
 
                                        Procedure 
   Less    
than 1x      
month 
 
1x  
month  
 About 
Once 
Every 
2 Weeks 
 
     1x a      
    week 
   Daily 
N/A 
Or 0 times 
A. Teacher rating forms (e.g., Child 
Behavior Checklist, Behavior 
Assessment Scale for Children) 
1 2 3 4 5 N/A 
B. Direct behavior observations 1 2 3 4 5 N/A 
C. Parent rating forms (e.g., Child 
Behavior Checklist, Behavior 
Assessment Scale for Children) 
1 2 3 4 5 N/A 
D. Parent interviews 1 2 3 4 5 N/A 
E. Child self report via rating scale 
(e.g., CBCL, Children’s Depression   
Inventory, Reynolds Children’s 
Manifest Anxiety Scale) 
1 2 3 4 5 N/A 
F. Child interview  1 2 3 4 5 N/A 
G. Teacher interview  1 2 3 4 5 N/A 
H. Permanent products (e.g., work 
samples) 1 2 3 4 5 N/A 
I. Curriculum based assessment  1 2 3 4 5 N/A 
J.Grades 1 2 3 4 5 N/A 
K. Other (please specify in the space 
below) 
_______________________________ 
1 2 3 4 5 N/A 
 
 
21.   To what extent do you agree or disagree that each of the following factors is a barrier to school 
psychologists monitoring psychotropic medications students are taking? 
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                              Factor  Strongly 
Disagree Disagree 
Neither Agree 
nor Disagree Agree 
Strongly 
Agree 
A.   Lack of Time 1 2 3 4 5 
B. Insufficient Knowledge 
(e.g., how to monitor 
medications and/or training 
on medication monitoring) 
1 2 3 4 5 
C. Lack of Resources (e.g., 
availability of rating scales 
and communication with 
outside providers).  
1 2 3 4 5 
C.   Lack of Teacher Support  1 2 3 4 5 
D. Lack of Support of other 
colleagues (e.g., school-
based   student assistance 
team members) 
1 2 3 4 5 
E.   Lack of Parent Support 
(e.g., parent 
permission/cooperation) 
1 2 3 4 5 
E. Lack of School-based 
administrative support   
(e.g., principal and vice 
principal)                                                                                               
1 2 3 4 5 
G.   Lack of Support of school 
psychologist’s supervisor 1 2 3 4 5 
H.   Teacher Availability (e.g., 
for consultation, progress        
monitoring, review of work 
samples)   
1 2 3 4 5 
I.     Lack of Community 
Support (e.g., collaborative 
relationships with 
mental/physical health 
providers in the 
community) 
1 2 3 4 5 
J.    Other Barriers not listed 
above (please write in)  
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22.  Given the listing of potential barriers in the previous question, please list what you feel may be a 
facilitator to school  
        psychologists monitoring psychotropic medications: 
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________ 
______________________________________________________________________________________ 
Lastly, please use the space below to add any comments about this topic or survey: 
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________ 
______________________________________________________________________________ 
           
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
           
           End of Survey.  Thank you!  
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